CN118525084A

CN118525084A - Use of tumor-infiltrating lymphocytes in the treatment of disease

Info

Publication number: CN118525084A
Application number: CN202380015383.7A
Authority: CN
Inventors: 刘雅容; 种孟阳
Original assignee: Shenzhen Shali Biotechnology Co ltd; Shanghai Grit Biotechnology Co Ltd; Suzhou Grit Biotechnology Co Ltd; Zhuhai Tuoyu Biotechnology Co Ltd
Current assignee: Shenzhen Shali Biotechnology Co ltd; Shanghai Grit Biotechnology Co Ltd; Suzhou Grit Biotechnology Co Ltd; Zhuhai Tuoyu Biotechnology Co Ltd
Priority date: 2022-01-19
Filing date: 2023-01-18
Publication date: 2024-08-20
Also published as: WO2023138598A1

Abstract

Use of tumor-infiltrating lymphocytes in the treatment of a disease, in particular, a tumor-infiltrating lymphocytes (TIL) for the preparation of a medicament for the prevention and/or treatment of a tumor, the TIL being obtained by a culture method comprising: the TIL derived from the tumor tissue is subjected to at least one stage of in vitro expansion, wherein in a single in vitro expansion stage, the in vitro expanded and/or non-in vitro expanded TIL is co-cultured with feeder cells after a certain time of contact with a T cell activator and/or a T cell growth factor.

Description

Use of tumor-infiltrating lymphocytes in the treatment of disease

Technical Field

The application relates to the field of biological medicine, in particular to application of tumor-infiltrating lymphocytes in disease treatment.

Background

Treatment of tumors using adoptive autologous metastatic tumor infiltrating lymphocytes is an effective method for treating patients with poor prognosis. However, adoptive autologous metastasis of tumor-infiltrating lymphocytes for treating tumors requires a large amount of tumor-infiltrating lymphocytes, and the current tumor-infiltrating lymphocytes from the patient tumors have weak expansion capacity and weak cell functions.

It is therefore a great need to solve the problem how to provide a robust and reliable tumor infiltrating lymphocyte that can be used in cell therapy.

Disclosure of Invention

The application provides an application of tumor infiltrating lymphocytes in disease treatment. The tumor-infiltrating lymphocytes obtained by the culture method disclosed by the application can show effectiveness and safety in tumor treatment.

In one aspect, the application provides the use of tumor-infiltrating lymphocytes (TILs) for the preparation of a medicament for the prevention and/or treatment of tumors, the TILs being obtained by the following culture method: the TIL derived from the tumor tissue is subjected to at least one stage of in vitro expansion, wherein in a single in vitro expansion stage, the in vitro expanded and/or non-in vitro expanded TIL is co-cultured with feeder cells after a certain time of contact with a T cell activator and/or a T cell growth factor.

In one aspect, the application provides the use of tumor-infiltrating lymphocytes (TILs) for the preparation of a medicament for the prevention and/or treatment of tumors, the TILs being obtained by the following culture method:

(A) Contacting a first population of TILs derived from tumor tissue and not expanded in vitro with T cell growth factors, wherein a second population of TILs is obtained via said step (a);

(B) Co-culturing the second population of TILs with feeder cells after a time of contact with a T cell activator and/or a T cell growth factor, wherein a third population of TILs is obtained via step (B).

(A) Resuscitating and/or continuing to culture an in vitro population of TILs to obtain a second population of TILs, wherein the in vitro population of TILs comprises a population of TILs obtained by ex vivo expansion of a first population of TILs derived from tumor tissue and not expanded in vitro;

(B) Contacting the second population of TILs with a T cell activator and/or a T cell growth factor, wherein a third population of TILs is obtained via step (B);

(C) Co-culturing the third population of TILs with feeder cells, wherein a fourth population of TILs is obtained via step (C).

In one aspect, the application provides a pharmaceutical composition comprising a TIL obtained according to the culture method described in the application of the application, together with a substance that reduces the number of lymphocytes and/or a substance that maintains the proliferative capacity of said TIL.

In one aspect, the application provides a kit comprising a pharmaceutical composition according to the application.

Other aspects and advantages of the present application will become readily apparent to those skilled in the art from the following detailed description. Only exemplary embodiments of the present application are shown and described in the following detailed description. As those skilled in the art will recognize, the present disclosure enables one skilled in the art to make modifications to the disclosed embodiments without departing from the spirit and scope of the application as claimed. Accordingly, the drawings and descriptions of the present application are to be regarded as illustrative in nature and not as restrictive.

Drawings

The specific features of the application related to the application are shown in the appended claims. A better understanding of the features and advantages of the application in accordance with the present application will be obtained by reference to the exemplary embodiments and the accompanying drawings that are described in detail below. The drawings are briefly described as follows:

FIG. 1 shows the comparison of the proliferation capacity of TILs for donors A-1, A-2, A-3 and A-4, when cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of OKT3 and IL-2.

FIG. 2 shows a comparison of the proportion of CD45RA ^-CCR7⁺ central memory T cells (Tcm) in CD8 ⁺ or in CD4 ⁺ in TIL added to feeder cell cultures after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2 for donors B-1 and B-2.

FIG. 3 shows a comparison of the proportion of CD45RA ^-CCR7⁺ -centered memory T cells (Tcm) in CD8 ⁺ or in CD4 ⁺ in TIL added to feeder cell cultures after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2 for donors B-3, B-4 and B-5.

FIG. 4 shows a comparison of the proportion of CD4 ⁺CD25⁺Foxp3⁺ regulatory T cells (Treg) in TIL in feeder cell cultures after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2 for donors C-1 and C-2.

FIG. 5 shows a comparison of the proportion of PD1 ⁺ activated T cells in CD8 ⁺ or CD4 ⁺ and LAG3 ⁺ activated T cells in TIL added to feeder cell cultures after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2 for donors D-1 and D-2.

FIG. 6 shows a comparison of the proportion of CD28 ⁺ activated T cells in CD8 ⁺ in TIL added to feeder cell cultures after 0 hours, 24 hours or 48 hours of OKT3 and IL-2 addition for donors D-3, D-4 and D-5.

FIG. 7 shows a comparison of the proportion of CD103 ⁺CD39⁺ tumor-specific T cells in CD8 ⁺ or in CD4 ⁺ in TIL added to feeder cell cultures after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2 for donors E-1 and E-2.

FIG. 8 shows a comparison of the proportion of TCF1 ⁺ stem cell-like T cells in TIL in feeder cell culture after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2 for donors F-1 and F-2.

FIG. 9 shows the results of the cell proliferation capacity of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2.

FIG. 10 shows the results of the ratio of CD45RA ^-CCR7⁺ central memory T cells (Tcm) of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours, or 48 hours of OKT3 and IL-2 addition.

FIG. 11 shows the TCF1 ⁺ stem cell-like T cell fraction of cultured TIL cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2 in feeder cells.

FIG. 12 shows the proportion of CD4 ⁺CD25⁺Foxp3⁺ regulatory T cells (Treg) of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of OKT3 and IL-2 addition.

FIG. 13 shows the proportion of activated T cells (PD 1 ⁺) of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2.

FIG. 14 shows the proportion of CD103 ⁺CD39⁺ tumor-specific T cells of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2.

FIG. 15 shows the proportion of activated T cells (CD 28 ⁺) of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2.

FIG. 16 shows the proportion of activated T cells (41 BB ⁺) of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2.

FIG. 17 shows the proportion of activated T cells (CD 25 ⁺) of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2.

FIG. 18 shows the results of intracellular factor expression detection of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2.

FIG. 19 shows the results of cytokine secretion assays of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of OKT3 and IL-2 addition.

FIG. 20 shows results of cell proliferation capacity of TIL cells cultured after 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or 5 days after addition of OKT3 and IL-2.

FIG. 21 shows the CD8 ⁺ T cell fraction of TIL cells cultured at 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or 5 days after addition of OKT3 and IL-2.

FIG. 22 shows the proportion of CD45RO ⁺CD62L⁺ T cells in TIL cells cultured 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or 5 days after addition of OKT3 and IL-2.

FIG. 23 shows NK T cell fractions of TIL cells cultured with the addition of feeder cells after 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or 5 days of OKT3 and IL-2 addition.

FIG. 24 shows the proportion of CD4 ⁺CD25⁺Foxp3⁺ regulatory T cells (Treg) of TIL cells cultured 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or 5 days after addition of OKT3 and IL-2.

FIG. 25 shows the results of cell killing ability of TIL cells cultured with feeder cells 48 hours after addition of OKT3 and IL-2.

Fig. 26A and 26B show imaging results of the treatment methods of the present application as embodied in the clinic.

Detailed Description

Further advantages and effects of the present application will become readily apparent to those skilled in the art from the present disclosure, by describing embodiments of the present application with specific examples.

Definition of terms

In the present application, the term "cyclophosphamide" generally refers to a preparation that treats cells. For example, a mustard alkylating agent, which may add alkyl groups (C _nH_2n+1) to DNA. For example, cyclophosphamide may refer to the formula C ₇H₁₅Cl₂N₂O₂P·H₂ O, chemical name 2- [ bis (2-chloroethyl) amino ] tetrahydro-2H-1, 3, 2-oxazaphosphacycle 2-oxide monohydrate. For example, cyclophosphamide can have a CAS registry number of 50-18-0. Cyclophosphamide may be commercially available.

In the present application, the term "fludarabine" generally refers to a preparation that treats cells. Such as a fluorinated nucleotide analog. For example, fludarabine may refer to an agent having the formula C ₁₀H₁₂FN₅O₄, CAS registry number 21679-14-1.

In the present application, the term "expression" generally refers to the transcription and/or translation process that occurs in a cell of a gene encoding a polypeptide of interest. The level of transcription of a gene encoding a polypeptide of interest in a host cell can be determined by measuring the amount of the corresponding mRNA present in the cell. For example, quantitative measurement of mRNA transcribed from a gene encoding a polypeptide of interest can be performed by PCR or by RNA hybridization. The level of translation of the gene encoding the polypeptide of interest can be measured by a variety of methods, for example by ELISA, by polypeptide bioactivity assays, or by western blotting or radioimmunoassay.

In the present application, the term "stage" of "one-stage in vitro amplification", "single in vitro amplification stage", or "first-stage in vitro amplification" or the like generally refers to a stage of an amplification process through which TIL passes in vitro. In one embodiment, each phase may be divided by a change in the number of TIL cells, and in one embodiment, when the number of TIL cells increases by at least about 1-fold, the TIL cells may be considered to have entered the in vitro expansion of the next phase. In some embodiments, a TIL cell can be considered to enter the next stage of in vitro expansion when the number of TIL cells is increased by at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 11-fold, at least about 12-fold, at least about 13-fold, at least about 14-fold, at least about 15-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold. In one embodiment, each phase may also be divided by the conditions under which the TIL cells are cultured. In one embodiment, when T cell costimulatory molecules and/or T cell growth factors are added or supplemented to the cell culture medium, the TIL cells can be considered to have entered the next stage of in vitro expansion. In one embodiment, after centrifugation and/or cell washing of the TIL cells, the TIL cells may be considered to have entered the next stage of in vitro expansion. In one embodiment, each phase may also be divided by the number of days the TIL cells are cultured. In one embodiment, the TIL cells may be considered to have entered the next stage of in vitro expansion after culturing the TIL cells in vitro for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 30 days, about 40 days, about 50 days, or about 100 days.

In the present application, the term "first stage of in vitro amplification" generally refers to the stage of amplification using T cell growth factors after primary TIL is obtained from tissue. In one embodiment, the tissue may be tumor tissue. In one embodiment, the amplification may be in vivo, performed autologous or allogeneic, or may be in vitro. The first stage amplification may also be referred to as preREP (rapid pre-amplification) stage.

In the present application, the term "in vitro amplification of the second stage" generally refers to a stage in which tissue taken from a subject is amplified and then amplified again. In one embodiment, the number of TIL cells expanded by the second stage is increased, e.g., by at least about 10-fold (or at least about 20, 30, 40, 50, 60, 70, 80, or 90-fold), or in one embodiment the number of cells may be increased by at least about 100-fold, as compared to TIL expanded by the first stage. In one embodiment, the second stage amplification may be different from the culture conditions of the first stage amplification, e.g., the culture material added may be different. The second stage amplification may also be referred to as the REP (rapid amplification) stage.

In the present application, the term "in vivo" generally refers to an event that occurs in a subject.

In the present application, the term "in vitro" generally refers to an event that occurs in vitro in a subject.

In the present application, the term "ex vivo" generally refers to an event involving treatment or surgery of cells, tissues and/or organs that have been removed from the body of a subject. In one embodiment, the cells, tissues and/or organs may be returned to the subject's body by surgical or therapeutic methods.

In the present application, the term "secretion" generally refers to the transfer of an expressed polypeptide or protein by a cell to the extracellular environment.

In the present application, the term "secretory capacity" generally refers to the ability of a cell to express a polypeptide or protein and to transfer the polypeptide or protein to the extracellular environment.

In the present application, the term "irradiation" generally refers to the treatment of a substance by radiation. For example, in one embodiment, irradiation may refer to irradiation of a substance by X-rays, alpha rays, beta rays, or gamma rays.

In the present application, the term "engineered cell" generally refers to a cell that has been genetically modified by adding additional genetic material in the form of DNA or RNA to the total genetic material of the cell. In one embodiment, the engineered cells may be genetically modified to express T cell costimulatory molecules and/or TILs of T cell growth factors according to the application.

In the present application, the term "co-culture" generally refers to the culturing of two or more different populations of cells with some degree of contact between them. The "contacting" of the two or more different populations of cells may be by direct contact, i.e., where one population of cells is in direct physical contact with the other population of cells, in one embodiment. Or in one embodiment may be indirectly contacted by a shared medium. The shared medium may contain metabolites produced and released by at least one population of co-cultured cells and used to culture cells of another population.

In the present application, the term "contacting" generally means that two or more different types of substances are contacted together in any order, in any manner, and for any period of time. In one embodiment, the TIL cells may be cultured by direct contact, e.g., a feeder cell, T cell costimulatory molecule, and/or T cell growth factor may be added to the culture medium of the TIL cells, and in one embodiment by indirect contact, e.g., a metabolite produced and released by the feeder cell.

In the present application, the term "mixture" generally refers to a combination of two or more different substances.

In the present application, the terms "simultaneous contact", "co-contact", "simultaneous with..contact", "simultaneous" and "co-with" generally refer to the administration of two or more substances to a subject such that the substances are present simultaneously in the subject and/or in the environment in which the subject is cultured. Simultaneous contacting may include simultaneous administration in different compositions, administration in different compositions at different times, or administration in compositions in which more than two active pharmaceutical ingredients are present.

In the present application, the term "amplification" generally refers to the increase in the number of cells by a factor of several times over a period of time. In one embodiment the number of cells may be increased by at least about 3 times (or 4, 5,6,7,8, or 9 times), in one embodiment the number of cells may be increased by at least about 10 times (or 20, 30, 40, 50, 60, 70, 80, or 90 times), or in one embodiment the number of cells may be increased by at least about 100 times. In the present application, the term "amplified" generally means that the cells have been subjected to one or more of the above-described amplifications.

In the present application, the term "polymer" generally refers to a molecule consisting of separate chemical moieties linked together, which moieties may be the same or different. In one embodiment, the term "polymer" may refer to separate chemical moieties that are linked tail to form a linear molecule, as well as separate chemical moieties that are linked together in a branched (e.g., "multi-arm" or "star") structure. In one embodiment the polymer may comprise, for example, a hydrogel, polyethylene glycol, or poloxamer. Poloxamers are nonionic triblock copolymers having a central hydrophobic chain of polyoxypropylene (poly (propylene oxide)) flanked by two hydrophilic chains of polyoxyethylene (poly (ethylene oxide)). The materials encompassed by the present application may be formulated with, or administered with, any of the polymers described herein or known in the art.

In the present application, the term "antibody" generally refers to an immunoglobulin that is reactive with a given protein or peptide or fragment thereof. Such antibodies include, but are not limited to, human antibodies, primatized antibodies, chimeric antibodies, monoclonal antibodies, monospecific antibodies, polyclonal antibodies, multispecific antibodies, nonspecific antibodies, bispecific antibodies, multispecific antibodies, humanized antibodies, synthetic antibodies, recombinant antibodies, hybrid antibodies, mutant antibodies, grafted conjugated antibodies (i.e., antibodies conjugated or fused to other proteins, radiolabels, cytotoxins), and antibodies generated in vitro. Antibodies can be from any class of antibodies, including but not limited to IgG, igA, igM, igD, and IgE, as well as antibodies from any subclass (e.g., igG1, igG2, igG3, and IgG 4). The antibody may have a heavy chain constant region selected from, for example, igG1, igG2, igG3, or IgG 4. Antibodies may also have a light chain selected from, for example, kappa (kappa) or lambda (lambda). The antibodies may be derived from any species including, but not limited to, mice, humans, camels, llamas, fish, sharks, goats, rabbits, chickens, and cattle. The constant region of an antibody can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of Fc receptor binding, antibody glycosylation, number of cysteine residues, effector cell function, or complement function). Typically, an antibody specifically binds to a predetermined antigen, e.g., an antigen associated with a disorder, e.g., an inflammatory, immune, autoimmune, neurodegenerative, metabolic, and/or malignant disorder.

In the present application, the term "anti-CD 3 antibody" generally refers to an antibody or variant thereof that targets CD3, such as a monoclonal antibody, including human, humanized, chimeric or murine antibodies, that target CD3 receptors in the T cell antigen receptor of mature T cells. The anti-CD 3 antibody may comprise OKT-3. anti-CD 3 antibodies may also include other anti-CD 3 antibodies including, for example, otelixizumab, teplizumab and visilizumab in one embodiment.

In the present application, the term "IL-2" or "IL2" generally refers to a T-cell growth factor known as interleukin 2, and includes all forms of IL-2, which may include human and mammalian forms, conservative amino acid substitutions, glycoforms or variants, or active fragments thereof, in one embodiment. The GeneID encoding the IL2 gene may be 3558.

In the present application, the term "antigen presenting cell", or "APC" generally refers to an immune system cell, such as a helper cell (e.g., B cell, dendritic cell, etc.), that displays an exogenous antigen complexed with a Major Histocompatibility Complex (MHC) on its surface. T cells can recognize these complexes using their T Cell Receptor (TCR). APCs can process antigens and present them to T cells. In one embodiment, the antigen presenting cell may comprise a polypeptide selected from the group consisting of: peripheral mononuclear cells, dendritic cells, and artificial antigen presenting cells.

In the present application, the term "TIL property" generally refers to the property of TIL cells obtained by the culture method of the present application. The change in TIL characteristics may comprise: increased number of TIL cells, increased proportion of viable cells, increased viability, improved proportion of T cell subsets, increased cytokine secretion capacity, increased tumor cell killing capacity, increased T Cell Receptor (TCR) clonal diversity and increased number of TIL cells in tissue and/or tumor, or any combination thereof. Variations of the application may be either up or down. In the present application, the term "amplification effect" generally refers to an effect that occurs after cells are amplified. The change in the amplification effect may include a change in the number and/or ratio of cells, a change in secretion capacity, a change in killing capacity or a change in expression capacity, or any combination thereof. The change may be an increase or decrease.

In the present application, the term "expanded" generally refers to cells that have been cultured to produce a change in the number of cells, the expanded cells may also produce a change in the number and/or ratio of cells, a change in secretion capacity, a change in killing capacity or a change in expression capacity, or any combination thereof. The change may be an increase or decrease.

In the present application, the term "nanoparticle" generally refers to at least one microscopic particle having a size of less than 100 nm. Typically, the nanoparticles have a diameter in the range of 50nm to 500nm (i.e., 0.05 μm to 0.5 μm); stable structure in physiological environment; and may house smaller molecules (e.g., drugs or other bioactive agents) that may then be delivered to the desired site.

In the present application, the term "artificial antigen presenting cell" generally refers to an artificially constructed cell of the immune system for displaying foreign antigens complexed with Major Histocompatibility Complex (MHC). In one embodiment, an isolated artificial antigen presenting cell (aAPC) may be included that may comprise cells expressing HLA-A/B/C (gene GeneID encoding it may be 3105, 3106 or 3107), CD64 (gene GeneID encoding it may be 2209), CD80 (gene GeneID encoding it may be 941), ICOS-L (gene GeneID encoding it may be 23308) and CD58 (gene GeneID encoding it may be 965), and may be modified to express more than one costimulatory molecule, which may comprise the present number.

In the present application, the term "fusion protein" generally refers to a polypeptide or protein that contains the amino acid sequence of a first polypeptide or protein or fragment, analog or derivative thereof and the amino acid sequence of a heterologous polypeptide or protein (i.e., a second polypeptide or protein or fragment, analog or derivative thereof that is different from the first polypeptide or protein or fragment, analog or derivative thereof, or is generally not part of the first polypeptide or protein or fragment, analog or derivative thereof). In some cases, the fusion protein may comprise a prophylactic or therapeutic drug fused to a heterologous protein, polypeptide or peptide. Wherein the heterologous protein, polypeptide or peptide may or may not be a different type of prophylactic or therapeutic drug. For example, two different proteins, polypeptides or peptides having immunomodulatory activity may be fused together to form a fusion protein. In some cases, the fusion protein may retain or increase activity as compared to the activity of the heterologous protein, polypeptide, or initial polypeptide or protein prior to fusion of the protein.

In the present application, the term "killing ability" generally refers to the effect achieved by contacting the cells with an effective amount of a substance to kill the target cells. In one embodiment, the substance may be a TIL cell. The killing may include killing the cells by itself or promoting CDC, apoptosis, ADCC, and/or phagocytosis of other cells or substances, or by a combination of two or more of these mechanisms.

In the present application, the term "administering" generally refers to delivering a substance to a subject in need thereof by any route known in the art. Pharmaceutically acceptable carriers and formulations or compositions are also well known in the art. The route of administration may include: intravenous, intramuscular, intradermal, subcutaneous, transdermal, mucosal, intratumoral and/or mucosal.

In the present application, the term "kit" generally refers to two or more components packaged together in a container, receptacle or other container, one of which corresponds to a substance of the present application. For example, TIL cells comprising the application.

In the present application, the term "subject" generally refers to a cell or animal, which may be a mammal, such as a human, a non-human primate (ape, gibbon, gorilla, chimpanzee, gorilla), a domestic animal (dog and cat), a farm animal (poultry such as chickens and ducks, horses, cattle, goats, sheep, pigs) and a laboratory animal (mouse, rat, rabbit, guinea pig). Human subjects include fetal, neonatal, infant, adolescent and adult subjects. Subjects include animal disease models, such as tumor animal models, and other animal models known to those of skill in the art.

In the present application, the term "feeder" generally refers to cultured cells that grow and secrete at least one factor into the culture medium in vitro and may be used to support the growth of another cell of interest in culture. In one embodiment, the feeder cells can include antigen presenting cells.

In the present application, the term "specifically binds" generally refers to antibodies that recognize a specific antigen, but do not substantially recognize or bind other molecules in the sample. For example, if an antibody can specifically bind to the specific antigen from one species, the antibody can also specifically bind to the antigen or cognate antigen from one or more other species. Such an intersystem reactivity may not itself alter the classification of antibodies as specific. In some cases, antibodies that specifically bind to an antigen may also bind to different allelic forms of the antigen.

In the present application, the term "complete culture process" generally refers to the complete process of separating cells from tumor tissue isolated from a patient, and finally obtaining cells that can be administered to a subject after one or more amplifications.

In the present application, the term "cell culture medium" generally refers to a nutrient solution in which cells, such as mammalian cells, are grown. The formulation of cell culture media is well known in the art. Typically, the cell culture medium includes buffers, salts, carbohydrates, amino acids, vitamins, and essential trace elements. The cell culture medium may or may not contain serum, peptone, and/or protein. The cell culture medium may be supplemented with additional components or components of increased concentration, such as amino acids, salts, sugars, vitamins, hormones, growth factors, buffers, antibiotics, lipids, trace elements, etc., depending on the requirements of the cells to be cultured and/or the desired cell culture parameters.

In the present application, the term "pharmaceutical formulation" or "pharmaceutical composition" generally refers to a preparation that may allow for the biological activity of the active ingredient to be effective and may be free of additional components that are unacceptably toxic to the subject to which the formulation is to be administered. Such formulations are sterile. "pharmaceutically acceptable" excipients (carriers, additives) are those which can be reasonably administered to a subject mammal to provide an effective dose of the active ingredient used.

In the present application, the term "tumor-infiltrating lymphocytes" or "TILs" generally refers to a population of cells initially obtained as white blood cells that have left the blood stream of a subject and migrated into a tumor. TILs may include, but are not limited to, CD8 ⁺ cytotoxic T cells (lymphocytes), th1 and Th17CD4 ⁺ T cells, natural killer cells, dendritic cells, and M1 macrophages. The TIL may include a primary TIL and a secondary TIL. "Primary TILs" may be those TIL cells obtained from a tissue sample of a subject, and "secondary TILs" may be any population of TIL cells that have been or have been expanded in the present application. In some embodiments, the tumor-infiltrating lymphocytes may be non-isolated and purified, or may be inter-infiltrating with tumor cells. In one embodiment, the TIL of the present application may refer to a population of TIL cells.

In the present application, "CD4 ⁺ cells" generally refer to CD4 positive cells, which may be T cells, for example. The terms "CD4 ⁺ cells", "CD4 positive cells" may be used synonymously. These cells can be identified by methods known in the art, for example, by staining the cells with a fluorescently labeled antibody to CD4 and sorting the cells using fluorescence activation. For example, the data presented demonstrate that an increase in the proportion of CD4 ⁺ cells results in an increase in the ability of the cell population to secrete IFN-gamma and/or TNF, and an increase in the tumor-inhibiting effect of the T cell population. For example, please see Tay, r.e., richardson, e.k., et al (2020), CANCER GENE THERAPY,1-13, but the art lacks a method for increasing the proportion of CD4 ⁺ cells, the present application provides a method for affecting the proportion of CD4 ⁺ cells.

In the present application, "CD8 ⁺ cells" generally refer to CD8 positive cells, which may be T cells, for example. The terms "CD8 ⁺ cells", "CD8 positive cells" may be used synonymously. These cells can be identified by methods known in the art, for example, by staining the cells with a fluorescently labeled antibody to CD8 and sorting the cells using fluorescence activation.

In the present application, the term "central memory T cell" generally refers to a T cell that has long-term memory and is capable of receiving antigen re-stimulation. The central memory T cell may have a phenotype of CD45RA ^-CCR7⁺, for example, central memory T cells may be identified by CD45RA ^- and CCR7 ⁺. For another example, the central memory T cell may have a phenotype of CD45RO ⁺CD62L⁺, such as by identifying the central memory T cell by CD45RO ⁺ and CD62L ⁺. The central memory T cell has stronger anti-tumor growth capacity than the common T cell.

In the present application, the term "regulatory T cells" generally refers to a class of T cell subsets that control autoimmune reactivity in vivo. Regulatory T cells may have the phenotype of CD4 ⁺CD25⁺Foxp3⁺, for example, they may be identified by CD4 ⁺、CD25⁺ and Foxp3 ⁺. Regulatory T cells may have the ability to inhibit the anti-tumor growth of T cells.

In the present application, the term "activated T cell" generally refers to a T cell that has been activated to have the ability to resist tumor growth. The activated T cells may have a phenotype of PD1 ⁺、LAG3⁺ or CD28 ⁺, for example, the activated T cells may be identified by PD1 ⁺、LAG3⁺ or CD28 ⁺. Activated T cells may have the ability to resist tumor growth.

In the present application, the term "tumor-specific T cell" generally refers to a T cell that can specifically resist tumor growth. The tumor-specific T cells may have a phenotype of CD103 ⁺CD39⁺, for example, the identification of tumor-specific T cells by CD103 ⁺ and CD39 ⁺. Tumor-specific T cells may have a more specific capacity for anti-tumor growth than normal T cells.

In the present application, the term "stem cell-like T cells" generally refers to a class of T cells that may have the potential to self-proliferate and/or differentiate. The stem cell-like T cell may have a phenotype of TCF1 ⁺, for example, it may be identified by TCF1 ⁺. Tumor-specific T cells may have a stronger and/or longer-term anti-tumor growth capacity than normal T cells.

In the present application, the term "NK cell" is also referred to as "natural killer cell", and generally refers to a cell having large particles in the cytoplasm. NK cells develop from bone marrow lymphoid stem cells and can differentiate and develop depending on the bone marrow or thymus microenvironment. In the present application, the proportion of NK cells in TIL cells can be changed by the method of the present application.

In the present application, the term "tumor fragments" generally refers to tumor fragments that can be formed by a disruption method after removing tumor tissue from a subject.

In the present application, the term "composition" or "pharmaceutical composition" generally refers to a mixture of at least one cell and at least one and optionally more than one other pharmaceutically acceptable chemical component such as a carrier, stabilizer, diluent, dispersant, suspending agent, thickener and/or excipient.

In the present application, the term "pharmaceutically acceptable carrier" generally refers to one or more non-toxic materials that do not interfere with the effectiveness of the biological activity of the active ingredient. Such formulations may conveniently contain salts, buffers, preservatives, compatible carriers, and optionally other therapeutic agents. Such pharmaceutically acceptable formulations may also contain compatible solid or liquid fillers, diluents or encapsulating substances suitable for administration to a human. Other contemplated carriers, excipients, and/or additives that may be used in the formulations described herein may include: for example, flavoring agents, antimicrobial agents, sweeteners, antioxidants, antistatic agents, lipids, protein excipients (e.g., serum albumin, gelatin, casein), salt forming counterions (e.g., sodium), and the like. These and other known pharmaceutical carriers, excipients and/or additives suitable for use in the formulations described herein are known in the art.

In the present application, the term "T cell costimulatory molecule" generally refers to a ligand that binds to a corresponding binding receptor on a T cell and mediates a T cell costimulatory response. The co-stimulatory molecule may be a cell surface molecule other than an antigen receptor or ligand thereof required for an effective immune response. Co-stimulatory molecules may include, but are not limited to, MHC class I molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte activating molecules (SLAM proteins), NK cell activating receptors, BTLA (the gene GeneID encoding it may be 151888), toll ligand receptors, OX40 (the gene GeneID encoding it may be 7293), CD2 (the gene GeneID encoding it may be 914), CD7 (the gene GeneID encoding it may be 924), CD27 (the gene GeneID encoding it may be 939), and, CD28 (the gene GeneID encoding it may be 940), CD30 (the gene GeneID encoding it may be 943), CD40 (the gene GeneID encoding it may be 958), CDS, ICAM-1 (the gene GeneID encoding it may be 3383), LFA-1 (CD 11a/CD 18) (the gene GeneID encoding it may be 3689), 4-1BB (CD 137) (the gene GeneID encoding it may be 3604), B7-H3 (the gene GeneID encoding it may be 80381), lfThe, ICOS (CD 278) (the gene GeneID encoding it may be 29851), GITR (the gene GeneID encoding it may be 8784), BAFFR (the gene GeneID encoding it may be 115650), LIGHT (the gene GeneID encoding it may be 8740), HVEM (LIGHT) (the gene GeneID encoding it may be 8764), KIRDS2, SLAMF7 (the gene GeneID encoding it may be 57823), NKp80 (KLRF 1) (the gene GeneID encoding it may be 51348), and, NKp44 (the gene GeneID encoding it may be 9436), NKp30 (the gene GeneID encoding it may be 259197), NKp46 (the gene GeneID encoding it may be 9437), CD19 (the gene GeneID encoding it may be 930), CD4 (the gene GeneID encoding it may be 920), CD8 a (the gene GeneID encoding it may be 925), CD8 β (the gene GeneID encoding it may be 926), IL-2rβ, IL-2rγ, IL7rα (the gene GeneID encoding it may be), and, ITGA4 (the gene GeneID encoding it may be 3676), VLA1 (the gene GeneID encoding it may be 3672), CD49a (the gene GeneID encoding it may be 3672), IA4 (the gene GeneID encoding it may be 3732), CD49D (the gene GeneID encoding it may be 3676), ITGA6 (the gene GeneID encoding it may be 3655), VLA-6 (the gene GeneID encoding it may be 3655), CD49f, CD49D (the gene GeneID encoding it may be 3655), ITGAD (the gene GeneID encoding it may be 3681), CD11d (the gene GeneID encoding it may be 3681), ITGAE (the gene GeneID encoding it may be 3682), CD103 (the gene GeneID encoding it may be 3682), ITGAL (the gene GeneID encoding it may be 3683), CD11a (the gene GeneID encoding it may be 3683), LFA-1 (the gene GeneID encoding it may be 3683), ITGAM (the gene GeneID encoding it may be 3684), CD11b (the gene GeneID encoding it may be 3684), ITGAX (the gene GeneID encoding it may be 3687), CD11c (the gene GeneID encoding it may be 3687), ITGB1 (the gene GeneID encoding it may be 3688), CD29 (the gene GeneID encoding it may be 3688), ITGB2 (the gene GeneID encoding it may be 3689), CD18 (the gene GeneID encoding it may be 3689), LFA-1 (the gene GeneID encoding it may be 3689), ITGB7 (the gene GeneID encoding it may be 3695), NKG2D (the gene GeneID encoding it may be 22914), NKG2C (the gene GeneID encoding it may be 3822), TNFR2 (the gene GeneID encoding it may be 7133), TRANCE/RANKL (the gene GeneID encoding it may be 8600), DNAM1 (CD 226) (the gene GeneID encoding it may be 10666), SLAMF4 (CD 244, 2B 4) (the gene GeneID encoding it may be 51744), and, CD84 (the gene GeneID encoding it may be 8832), CD96 (Tactile) (the gene GeneID encoding it may be 10225), CEACAM1 (the gene GeneID encoding it may be 634), CRTAM (the gene GeneID encoding it may be 56253), ly9 (CD 229) (the gene GeneID encoding it may be 4063), CD160 (BY 55) (the gene GeneID encoding it may be 11126), PSGL1 (the gene GeneID encoding it may be 6404), and, CD100 (SEMA 4D) (the gene GeneID encoding it may be 10507), CD69 (the gene GeneID encoding it may be 969), SLAMF6 (NTB-A, ly 108) (the gene GeneID encoding it may be 114836), SLAM (SLAMF 1, CD150, IPO-3) (the gene GeneID encoding it may be 6504), BLAME (SLAMF 8) (the gene GeneID encoding it may be 56833), SELPLG (CD 162) (the gene GeneID encoding it may be 6404), LTBR (the gene GeneID encoding it may be 4055), LAT (the gene GeneID encoding it may be 27040), GADS (the gene GeneID encoding it may be 9402), SLP-76 (the gene GeneID encoding it may be 3937), PAG/Cbp (the gene GeneID encoding it may be 55824), CD19a, and a ligand that specifically binds CD3, a ligand that specifically binds CD28, a ligand that specifically binds HVEM, a ligand that specifically binds CD40L, a ligand that specifically binds OX40, and a ligand that specifically binds 4-1 BB. The co-stimulatory intracellular signaling domain refers to the intracellular portion of the co-stimulatory molecule. The intracellular signaling domain may comprise the complete intracellular portion of the molecule from which it is derived or the complete native intracellular signaling domain or a functional fragment thereof.

In the present application, the term "T cell growth factor" generally refers to a biologically active polypeptide or small molecule compound that directs cell proliferation. In one embodiment, the T cell growth factor may be selected from one or more of the following group: IL-2 (the gene GeneID encoding it may be 3558), IL-4 (the gene GeneID encoding it may be 3565), IL-7 (the gene GeneID encoding it may be 3574), IL-10 (the gene GeneID encoding it may be 3586), IL-12 (the gene GeneID encoding it may be 3592 or 3593), IL-15 (the gene GeneID encoding it may be 3600), and gamma interferon (the gene GeneID encoding it may be 3458).

In the present application, the term "substantially simultaneously" generally means that the TIL may be contacted with more than two substances simultaneously over a period of time during the contacting process, but may not be limited to the TIL always being contacted with more than two substances simultaneously throughout the contacting process. For example, substantially simultaneously may mean that the TIL may be contacted with at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% of each of the two or more substances simultaneously over a period of time.

In the present application, the term "tumor" generally refers to any new pathological tissue proliferation. The tumors of the application may be benign or malignant. The tumors of the application may be solid or hematological. The term "tumor" may be selected from one or more of the following groups: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer, and renal cancer.

In the present application, the term "tumor tissue" generally refers to a sample from a tumor in a subject, including any solid tumor and/or any tissue that is not a solid tumor in a subject.

In the present application, the terms "about" and "approximately" generally refer to a range of values that are statistically significant. Such a range may be within an order of magnitude of a given value or range, may be included within 50%, may be included within 20%, may be included within 10%, and may be included within 5%. The term "about" or "approximately" includes permissible variations depending on the particular system under study, and can be readily appreciated by one of ordinary skill in the art. The terms "above," "below," "up to," and "at least" may include the present numbers.

Detailed Description

In one aspect, the application relates to the use of tumor-infiltrating lymphocytes (TILs) in the treatment of a disease, the medicament being for the prevention and/or treatment of a tumor, wherein the tumor-infiltrating lymphocytes are cultured as follows. For example, the expanded TIL may be co-cultured with feeder cells after contact with T cell co-stimulatory molecules and/or T cell growth factors. In one aspect, the application provides a method of culturing tumor-infiltrating lymphocytes (TILs), comprising: the expanded TIL may be co-cultured with feeder cells after a period of contact with the T cell costimulatory molecules and/or T cell growth factors. In one embodiment, the amplified TIL may be an in vitro amplified TIL.

For example, it may be provided that the number of lymphocytes in a subject is reduced prior to administration of the TIL obtained by the culture method to the subject. For example, in order to increase the efficacy of the TIL of the present application, the subject may be treated with the lymphatic system and/or lymphocytes. For example, lymphocytes of the subject may be cleared or substantially cleared, lymphocytes of the subject may be depleted or substantially depleted, or lymphocytes of the subject may be depleted or substantially depleted. For example, the treatment of the application may reduce the lymphocyte count of a subject by at least about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 19%, about 18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, or about 0.1% relative to that prior to the treatment.

For example, the reduction of lymphocyte numbers in the subject of the application comprises a stranguria-clearing regimen. For example, a stranguria-clearing regimen of the present application may comprise administering cyclophosphamide and/or fludarabine to a subject prior to administering to the subject the TIL obtained by the culturing method. For example, it may further comprise administering cyclophosphamide and/or fludarabine to the subject on days 4 to 2 prior to administering the TIL obtained by the culture method to the subject.

For example, cyclophosphamide can be administered to the subject at a dose of about 300 to about 500mg/m ²/day. For example, cyclophosphamide can be administered to the subject at a dose of about 50mg/m ²/day, about 100mg/m ²/day, about 150mg/m ²/day, about 200mg/m ²/day, about 250mg/m ²/day, about 300mg/m ²/day, about 350mg/m ²/day, about 400mg/m ²/day, about 450mg/m ²/day, or about 500mg/m ²/day. For example, cyclophosphamide can be administered to the subject for 3 days. For example, cyclophosphamide may be administered to the subject on days 4 to 2 prior to administration of TIL.

For example, fludarabine may be administered to the subject at a dose of about 20 to about 30mg/m ²/day. For example, fludarabine may be administered to the subject at a dose of about 5mg/m ²/day, about 10mg/m ²/day, about 15mg/m ²/day, about 20mg/m ²/day, about 25mg/m ²/day, or about 30mg/m ²/day. For example, fludarabine may be administered to the subject for 3 days. For example, fludarabine may be administered to the subject from day 4 to day 2 prior to administration of TIL.

In some embodiments, the amount of TIL provided in the compositions of the present application may range from about 5 x 10 ⁹ to 1 x 10 ¹⁰, from about 1 x 10 ¹⁰ to 5 x 10 ¹⁰, or from about 5 x 10 ¹⁰ to 1 x 10 ¹¹. In some embodiments, the amount of TIL provided in the compositions of the present application may range from about 5 x 10 ⁹, about 1 x 10 ¹⁰, about 5 x 10 ¹⁰, or about 1 x 10 ¹¹. For example, the TIL obtained by administering the culture method may be included as a single intravenous infusion to the subject. For example, the TIL obtained by administering the culture method may be included in a plurality of intravenous infusions to the subject.

For example, it may also comprise that the TIL obtained by the culture method may be maintained in proliferative capacity after administration to a subject. For example, it may further comprise administering interleukin-2 (IL-2) or a variant thereof to the subject after administering the TIL obtained by the culturing method to the subject.

For example, IL-2 may be administered to the subject at a dose of about 200,000 to about 600,000IU/kg/dose. For example, IL-2 may be administered to the subject at a dose of about 100,000 IU/kg/time, about 200,000 IU/kg/time, about 300,000IU/kg/time, about 400,000IU/kg/time, about 500,000 IU/kg/time, or about 600,000IU/kg/time.

For example, IL-2 may be administered to a subject for the first time 8 to 16 hours after the TIL obtained by the culture method is administered to the subject.

For example, after the first administration of IL-2 to the subject, IL-2 may be administered to the subject every 12 hours. For example, after the first administration of IL-2, the administration of IL-2 may be suspended once; whether to continue administration of IL-2 may be determined, for example, based on the patient's tolerance level. For example, 24 hours after the first administration of IL-2 to the subject, the IL-2 may be administered a second time, depending on the tolerability of the subject. For example, whether to continue administration of IL-2 may be determined based on adverse events in the subject. For example, IL-2 may be administered to the subject 10 times or less.

In one embodiment, the amplified TIL is a TIL obtained after at least one stage of in vitro amplification of a TIL derived from tumor tissue and not amplified in vitro. For example, the in vitro amplification may be through at least 2 stages, the in vitro amplification may be through at least 3 stages, the in vitro amplification may be through at least 4 stages, the in vitro amplification may be through at least 5 stages, the in vitro amplification may be through at least 6 stages, the in vitro amplification may be through at least 7 stages, the in vitro amplification may be through at least 8 stages, the in vitro amplification may be through at least 9 stages, or the in vitro amplification may be through at least 10 stages.

For example, each stage of in vitro expansion may be divided by a change in the number of TIL cells, e.g., when the number of TIL cells increases by at least about 1-fold, the TIL cells may be considered to have entered the next stage of in vitro expansion. In some embodiments, a TIL cell may be considered to have entered the next stage of in vitro expansion when the number of TIL cells is increased by at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 11-fold, at least about 12-fold, at least about 13-fold, at least about 14-fold, at least about 15-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or at least about 1000-fold. For example, the in vitro expansion of each stage may also be divided by the variation in conditions of the TIL cell culture. For example, when T cell activators and/or T cell growth factors are added to or supplemented with the cell culture medium, the TIL cells can be considered to have entered the next stage of in vitro expansion. For example, T cell activators of the application may be used interchangeably with T cell costimulatory molecules. For example, when IL-2 is added or supplemented to the cell culture medium, the TIL cells can be considered to have undergone in vitro expansion at the next stage. For example, when feeder cells are added or supplemented to the cell culture medium, the TIL cells can be considered to have undergone a subsequent stage of in vitro expansion. For example, when the TIL cells are subjected to centrifugation and/or cell washing, the TIL cells can be considered to have been expanded in vitro to the next stage. For example, each phase may be divided by the number of days the TIL cells are cultured. For example, a TIL cell may be considered to have entered the next stage of in vitro expansion after culturing the TIL cell in vitro for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 30 days, about 40 days, about 50 days, or about 100 days.

For example, the second stage in vitro amplification may be performed for at least about 7 days. For example, the second stage in vitro amplification may be performed for at least about 9 days. For example, the second stage in vitro amplification may be performed for up to about 14 days. For example, the second stage in vitro amplification may be performed for up to about 13 days. For example, the second stage in vitro amplification may be performed for about 7 days to about 14 days, about 9 days to about 14 days, about 7 days to about 13 days, or about 9 days to about 13 days. For example, the second stage in vitro amplification of the present application may be performed for at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, or at least about 14 days. For example, the second stage in vitro amplification of the present application may be performed for about 9 days to about 14 days, e.g., the second stage in vitro amplification of the present application may be performed for about 9 days to about 14 days, about 10 days to about 14 days, about 11 days to about 14 days, about 12 days to about 14 days, about 13 days to about 14 days, about 9 days to about 13 days, about 10 days to about 13 days, about 11 days to about 13 days, about 12 days to about 13 days, about 9 days to about 12 days, about 10 days to about 12 days, about 11 days to about 12 days, or about 10 days to about 11 days. For example, the second stage in vitro amplification of the present application may be considered as stage REP (rapid expansion protocol).

For example, the first stage in vitro amplification may be performed for at least about 7 days. For example, the first stage in vitro amplification may be performed for about 7 days to about 14 days. For example, the first stage in vitro amplification of the application may be performed for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, or at least about 14 days. For example, the first stage in vitro amplification of the present application may be performed for about 7 days to about 14 days, about 8 days to about 14 days, about 9 days to about 14 days, about 10 days to about 14 days, about 11 days to about 14 days, about 12 days to about 14 days, about 13 days to about 14 days, about 9 days to about 13 days, about 10 days to about 13 days, about 11 days to about 13 days, about 12 days to about 13 days, about 9 days to about 12 days, about 10 days to about 12 days, about 11 days to about 12 days, or about 10 days to about 11 days. For example, the first stage in vitro amplification of the present application may be considered as stage preREP.

For example, the number of days for which the second-stage in vitro amplification of the present application is performed may be calculated from the start time of the second-stage in vitro amplification. For example, the time when the second-stage in vitro amplification was initiated, it can be considered that the second-stage in vitro amplification was increased by about 0 days. For example, about 24 hours after the initiation of the second-stage in vitro amplification may be considered to be about 1 day after the initiation of the second-stage in vitro amplification. For example, the day on which the second stage in vitro amplification begins may be considered to be about 0 days greater than the second stage in vitro amplification. For example, the number of days for which the second-stage in vitro amplification of the present application is performed may be calculated by the number of days for which the second-stage in vitro amplification is performed. For example, the second day after the initiation of the second-stage in vitro amplification may be considered to be about 1 day after the second-stage in vitro amplification.

For example, the culturing method of the TIL used in the present application may be divided in a two-step division manner. For example, (a) a first population of TILs derived from tumor tissue and not expanded in vitro may be contacted with a T cell growth factor, wherein a second population of TILs is obtained via said step (a); (B) The second population of TILs may be co-cultured with feeder cells after a time of contact with a T cell activator and/or a T cell growth factor, wherein a third population of TILs is obtained via step (B). For example, the step (a) may be performed for about 7 days to about 14 days. For example, the step (B) may be performed for about 7 days to about 14 days.

For example, the culturing method of the TIL used in the present application may be divided in a three-step division manner. For example, (a) a first population of TILs derived from tumor tissue and not expanded in vitro may be contacted with a T cell growth factor, wherein a second population of TILs is obtained via said step (a); (B) Contacting the second population of TILs with a T cell activator and/or a T cell growth factor, wherein a third population of TILs is obtained via step (B); (C) The third population of TILs may be co-cultured with feeder cells, wherein a fourth population of TILs is obtained via step (C). For example, the step (a) may be performed for about 7 days to about 14 days. For example, the step (B) may be performed for about 0 to about 8 days. For example, the step (C) may be performed for about 5 days to about 14 days.

For example, the cultivation method of the TIL used in the present application may be divided in a four-step division manner. For example, (a) a first population of TILs derived from tumor tissue and not expanded in vitro may be contacted with a T cell growth factor, wherein a second population of TILs is obtained via said step (a); (B) Contacting the second population of TILs with a T cell activator and/or a T cell growth factor, wherein a third population of TILs is obtained via step (B); (C) Increasing or decreasing the expression and/or increasing or decreasing the activity of an optional gene of the third TIL population, wherein a fourth TIL population is obtained via the step (C); (D) The fourth population of TILs may be co-cultured with feeder cells, wherein a fifth population of TILs is obtained via step (D). For example, the step (a) may be performed for about 7 days to about 14 days. For example, the step (B) may be performed for about 0 to about 4 days. For example, the step (C) may be performed for about 0 to about 4 days. For example, the step (D) may be performed for about 5 days to about 14 days.

For example, the improved TIL properties of the present application comprise one or more selected from the group consisting of: increased number of TIL cells, increased proportion of living cells, increased viability, improved proportion of T cell subsets, increased cytokine secretion, increased tumor cell killing, increased T Cell Receptor (TCR) clonal diversity and increased number of TIL cells in tissue and/or tumor.

In one embodiment, the expanded TIL may be co-cultured with feeder cells after contact with the T cell co-stimulatory molecule. In one embodiment, the expanded TIL may be co-cultured with feeder cells after contact with T cell growth factors. In one embodiment, the expanded TIL may be co-cultured with feeder cells after contact with the T cell costimulatory molecules and T cell growth factors. In one embodiment, the expanded TIL may be co-cultured with at least a portion of the feeder cells after contacting with the T cell costimulatory molecules and/or T cell growth factors. For example, a portion of the feeder cells may be co-cultured with the expanded TIL while the expanded TIL is in contact with the T cell costimulatory molecule and/or the T cell growth factor, and at least another portion of the feeder cells may be co-cultured with the expanded TIL after the expanded TIL is in contact with the T cell costimulatory molecule and/or the T cell growth factor. For example, at least another portion of the feeder cells can comprise about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 19%, about 18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, or about 0.1% of all feeder cells used.

In one embodiment, the expanded TIL cells may be expanded in vitro. In one embodiment, the expanded TIL cells may be expanded in vivo. In one embodiment, the expanded TIL cells may be expanded in vivo. In one embodiment, the expanded TIL cells may be expanded ex vivo.

In one embodiment, the amount of amplified TIL may be increased by at least a factor of 1 compared to the TIL derived from tumor tissue and not amplified in vitro. For example, the amount of the amplified TIL may be increased by at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 11-fold, at least about 12-fold, at least about 13-fold, at least about 14-fold, at least about 15-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold as compared to the TIL derived from tumor tissue and not amplified in vitro.

In one embodiment, the expanded TIL cells may increase the number of expanded TIL cells by more than 50-fold as compared to TIL obtained from tumor tissue and not expanded in vitro. For example, the expanded TIL cell number may be increased by about 50-fold or more, about 60-fold or more, about 70-fold or more, about 80-fold or more, about 90-fold or more, about 100-fold or more, about 200-fold or more, about 300-fold or more, about 400-fold or more, about 500-fold or more, about 600-fold or more, about 700-fold or more, about 800-fold or more, about 900-fold or more, about 2000-fold or more, about 3000-fold or more, about 4000-fold or more, about 5000-fold or more, about 6000-fold or more, about 7000-fold or more, about 8000-fold or more, about 9000-fold or more, about 10000-fold or more, about 15000-fold or more, or about 20000-fold or more, as compared to TIL obtained from tumor tissue. .

In one aspect, the application provides a method of culturing a TIL for use. Wherein the TIL expanded in the first stage is subjected to a second stage of expansion, wherein in the second stage of expansion the TIL may be co-cultured with feeder cells after contact with T cell co-stimulatory molecules and/or T cell growth factors.

In one embodiment, in the second stage of expansion, the TIL may be co-cultured with feeder cells after contact with a T cell co-stimulatory molecule. In one embodiment, in the second stage of expansion, the TIL may be co-cultured with feeder cells after contact with T cell growth factors. In one embodiment, in the second stage of expansion, the TIL may be co-cultured with feeder cells after contact with a T cell co-stimulatory molecule and a T cell growth factor. In one embodiment, in the second stage of expansion, the TIL may be co-cultured with at least a portion of the feeder cells after contact with the T cell co-stimulatory molecules and/or T cell growth factors. For example, in the second stage of expansion, a portion of the feeder cells may be co-cultured with the TIL while the TIL is in contact with the T cell costimulatory molecule and/or the T cell growth factor, and at least another portion of the feeder cells may be co-cultured with the TIL after the TIL is in contact with the T cell costimulatory molecule and/or the T cell growth factor. For example, at least another portion of the feeder cells can comprise about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 19%, about 18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, or about 0.1% of all feeder cells used.

For example, the present application may add the present feeder cells to the cell culture media of the present TIL in a ratio of about 40:1 to about 400:1 of the present feeder cells to the present TIL. For example, the present application may add the present application feeder cells to the present application's cell culture medium at a ratio of about 40:1 to about 400:1, about 40:1 to about 300:1, about 40:1 to about 200:1, about 40:1 to about 100:1, about 40:1 to about 90:1, about 40:1 to about 80:1, about 40:1 to about 70:1, about 40:1 to about 60:1, about 40:1 to about 50:1, about 50:1 to about 400:1, about 60:1 to about 400:1, about 70:1 to about 400:1, about 80:1 to about 400:1, about 90:1 to about 400:1, about 100:1 to about 400:1, about 200:1 to about 400:1, or about 300:1 to about 400:1 to the present application's TIL.

In one embodiment, the number of TIL cells expanded by the second stage may be increased by more than about 50-fold as compared to TIL expanded by the first stage. For example, the number of TIL cells expanded by the second stage may be increased by about 50-fold or more, about 60-fold or more, about 70-fold or more, about 80-fold or more, about 90-fold or more, about 100-fold or more, about 200-fold or more, about 300-fold or more, about 400-fold or more, about 500-fold or more, about 600-fold or more, about 700-fold or more, about 800-fold or more, about 900-fold or more, about 1000-fold or more, about 2000-fold or more, about 3000-fold or more, about 4000-fold or more, about 5000-fold or more, about 6000-fold or more, about 7000-fold or more, about 8000-fold or more, about 9000-fold or more, about 10000-fold or more, about 15000-fold or more, or about 20000-fold or more, as compared to TIL expanded by the first stage. In one embodiment, the increase in the number of TIL cells may be expressed as a fold of expansion, which may be the fold to which the number of TIL cells expands after the end of the second stage expansion compared to before the start of the second stage expansion. For example, if the number of TIL cells before the start of the second-stage expansion is 1×10 ⁸ and the number of TIL cells after the end of the second-stage expansion is 1×10 ⁹, it can be considered that the expansion factor of the TIL cells is 10.

In one aspect, the application provides a method of culturing a TIL for use, comprising: the TIL derived from the tumor tissue and not amplified in vitro may be subjected to at least one stage of in vitro amplification, wherein in a single in vitro amplification stage, the in vitro amplified and/or not amplified TIL may be co-cultured with feeder cells after a certain time of contact with T cell co-stimulatory molecules and/or T cell growth factors.

In another embodiment, TIL derived from tumor tissue and not amplified in vitro may be subjected to at least two stages of in vitro amplification, wherein in a single in vitro amplification stage after and/or after the second stage of in vitro amplification, the in vitro amplified and/or not amplified TIL may be co-cultured with feeder cells after a certain time of contact with T cell co-stimulatory molecules and/or T cell growth factors.

For example, TIL derived from tumor tissue and not amplified in vitro may be subjected to one stage of in vitro amplification, wherein in the first stage of in vitro amplification, TIL not amplified in vitro may be co-cultured with feeder cells after a certain time of contact with T cell co-stimulatory molecules and/or T cell growth factors.

For example, TIL derived from tumor tissue and not amplified in vitro may be subjected to two stages of in vitro amplification, wherein in the first stage of in vitro amplification, TIL not amplified in vitro may be co-cultured with feeder cells after a certain time of contact with T cell co-stimulatory molecules and/or T cell growth factors. Alternatively, TIL derived from tumor tissue and not subjected to in vitro expansion may be subjected to two stages of in vitro expansion, wherein in the second stage of in vitro expansion, the in vitro expanded TIL may be co-cultured with feeder cells after a certain time of contact with T cell costimulatory molecules and/or T cell growth factors.

For example, it is also possible to subject the in vitro expanded TIL derived from tumor tissue and not subjected to in vitro expansion in two stages, wherein in the in vitro expansion in the first stage the in vitro expanded TIL may be co-cultured with feeder cells after a certain time of contact with the T cell costimulatory molecules and/or T cell growth factors, and wherein in the in vitro expanded TIL in the second stage may be co-cultured with feeder cells after a certain time of contact with the T cell costimulatory molecules and/or T cell growth factors.

For example, TIL derived from tumor tissue and not amplified in vitro may be subjected to three stages of in vitro amplification, wherein in the first stage of in vitro amplification, TIL not amplified in vitro may be co-cultured with feeder cells after a certain time of contact with T cell co-stimulatory molecules and/or T cell growth factors. The TIL derived from tumor tissue and not amplified in vitro may also be subjected to three stages of in vitro amplification, wherein in the second stage of in vitro amplification, the in vitro amplified TIL may be co-cultured with feeder cells after a certain time of contact with T cell costimulatory molecules and/or T cell growth factors. The TIL derived from tumor tissue and not amplified in vitro may also be subjected to three stages of in vitro amplification, wherein in the third stage of in vitro amplification, the in vitro amplified TIL may be co-cultured with feeder cells after a certain time of contact with T cell costimulatory molecules and/or T cell growth factors.

For example, it is also possible to subject the in vitro expanded TIL derived from tumor tissue and not subjected to in vitro expansion in three stages, wherein in the in vitro expansion in the first stage, the in vitro expanded TIL may be co-cultured with feeder cells after a certain time of contact with the T cell costimulatory molecules and/or T cell growth factors, and wherein in the in vitro expansion in the second stage, the in vitro expanded TIL may be co-cultured with feeder cells after a certain time of contact with the T cell costimulatory molecules and/or T cell growth factors. For example, it is also possible to subject the in vitro expanded TIL derived from tumor tissue and not subjected to in vitro expansion in three stages, wherein in the in vitro expansion in the first stage, the in vitro expanded TIL may be co-cultured with feeder cells after a certain time of contact with the T cell costimulatory molecules and/or T cell growth factors, and wherein in the in vitro expanded TIL in the third stage may be co-cultured with feeder cells after a certain time of contact with the T cell costimulatory molecules and/or T cell growth factors. For example, it is also possible to subject the in vitro expanded TIL derived from tumor tissue and not subjected to in vitro expansion in three stages, wherein in the second stage of in vitro expansion, the in vitro expanded TIL may be co-cultured with feeder cells after a certain time of contact with the T cell costimulatory molecules and/or T cell growth factors, and wherein in the third stage of in vitro expansion, the in vitro expanded TIL may be co-cultured with feeder cells after a certain time of contact with the T cell costimulatory molecules and/or T cell growth factors. For example, it is also possible to subject the in vitro expanded TIL derived from tumor tissue and not subjected to in vitro expansion in three stages, wherein in the first stage of in vitro expansion, the in vitro expanded TIL can be co-cultured with the feeder cells after a certain time of contact with the T cell costimulatory molecules and/or T cell growth factors, and wherein in the second stage of in vitro expansion, the in vitro expanded TIL can be co-cultured with the feeder cells after a certain time of contact with the T cell costimulatory molecules and/or T cell growth factors, and wherein in the third stage of in vitro expansion, the in vitro expanded TIL can be co-cultured with the feeder cells after a certain time of contact with the T cell costimulatory molecules and/or T cell growth factors.

In one aspect, the application provides a method of culturing a TIL for use. Wherein the TIL may be co-cultured with feeder cells after contact with the T cell co-stimulatory molecules and/or T cell growth factors, wherein the TIL may undergo more than two stages of expansion during the complete culturing process, and wherein the TIL contact with the T cell co-stimulatory molecules and/or T cell growth factors may occur during expansion of the TIL and feeder cells at the same stage.

In one embodiment, the TIL may undergo more than two stages of expansion during the complete culture process, and the TIL may be co-cultured with feeder cells after contact with the T cell co-stimulatory molecule. In one embodiment, the TIL may undergo more than two stages of expansion during the complete culture process, and the TIL may be co-cultured with feeder cells after contact with the T cell growth factor. In one embodiment, the TIL may undergo more than two stages of expansion during the complete culture process, and the TIL may be co-cultured with feeder cells after contact with the T cell costimulatory molecules and T cell growth factors. In one embodiment, the TIL may undergo more than two stages of expansion during the complete culturing process, and the TIL may be co-cultured with at least a portion of the feeder cells after contact with the T cell costimulatory molecules and/or T cell growth factors. For example, the TIL may undergo more than two stages of expansion during the complete culturing process, and a portion of the feeder cells may be co-cultured with the TIL while the TIL is in contact with the T cell costimulatory molecules and/or the T cell growth factors, and at least another portion of the feeder cells may be co-cultured with the TIL after the TIL is in contact with the T cell costimulatory molecules and/or the T cell growth factors. For example, at least another portion of the feeder cells can comprise about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 19%, about 18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, or about 0.1% of all feeder cells used.

In one embodiment, the TIL may undergo more than two stages of amplification during the entire culture process. For example, the TIL may undergo amplification during the entire culture at more than 2,3, 4,5, 6, 7, 8, 9, 10, 20, 50, 100 stages.

In one embodiment, contacting a TIL with a T cell costimulatory molecule and/or a T cell growth factor with the TIL and feeder cells may occur in a first stage of expansion and/or a second stage of expansion. In one embodiment, contacting a TIL with a T cell costimulatory molecule and/or a T cell growth factor with the TIL and feeder cells can occur in a first stage of expansion, a second stage of expansion, and/or a third stage of expansion. For example, contacting a TIL with a T cell costimulatory molecule and/or a T cell growth factor with the TIL and feeder cells can occur in a first stage expansion. For example, contacting of the TIL with T cell costimulatory molecules and/or T cell growth factors with the TIL and feeder cells can occur in a second stage of expansion. For example, contacting a TIL with a T cell costimulatory molecule and/or a T cell growth factor with the TIL and feeder cells can occur in a third stage expansion. For example, contacting a TIL with a T cell costimulatory molecule and/or a T cell growth factor with the TIL and feeder cells can occur in a first stage of expansion and a second stage of expansion. For example, contacting a TIL with a T cell costimulatory molecule and/or a T cell growth factor with the TIL and feeder cells can occur in a first stage of expansion and a third stage of expansion. For example, contacting a TIL with a T cell costimulatory molecule and/or a T cell growth factor with the TIL and feeder cells can occur in a second stage of expansion and a third stage of expansion. For example, contacting a TIL with a T cell costimulatory molecule and/or a T cell growth factor with the TIL and feeder cells can occur in a first stage of expansion, a second stage of expansion, and a third stage of expansion.

In one embodiment, co-culturing the TIL with the feeder cells after contacting the TIL with the T cell co-stimulatory molecule and/or the T cell growth factor for a time interval may increase the expansion of the TIL as compared to co-culturing the TIL with the feeder cells while contacting the TIL with the T cell co-stimulatory molecule and the T cell growth factor. For example, the increasing the amplification effect of TIL may comprise a member selected from the group consisting of: increasing the number of TIL cells, changing the proportion of TIL cells, improving the secretion capacity of TIL cells, and improving the killing capacity of TIL cells. In one embodiment, co-culturing the TIL with feeder cells after contacting the TIL with a T cell co-stimulatory molecule and/or a T cell growth factor for a time interval may increase the number of TIL cells. In one embodiment, co-culturing the TIL with feeder cells after contacting the TIL with a T cell costimulatory molecule and/or a T cell growth factor for a time interval may increase the secretion capacity of the TIL cells. In one embodiment, co-culturing the TIL with feeder cells after contacting the TIL with a T cell costimulatory molecule and/or a T cell growth factor for a time interval may increase the killing capacity of the TIL cells.

In one embodiment, the ratio of TIL cells may be altered by co-culturing the TIL with feeder cells after the TIL is contacted with the T cell co-stimulatory molecule and/or T cell growth factor for a time interval. For example, the ratio of TIL cells that can be altered can include a factor selected from the group consisting of: the proportion of central memory T cells (Tcm) in the TIL may be increased, the proportion of TIL cells other than regulatory T cells (tregs) may be increased, the proportion of regulatory T cells (tregs) may be decreased, the proportion of activated T cells may be increased, the proportion of tumor-specific T cells may be increased, and the proportion of stem cell-like T cells may be increased. for example, the ratio of TIL cells that can be altered includes a factor selected from the group consisting of: can increase the proportion of CD45RA ^-CCR7⁺ central memory T cells (Tcm) in TIL, can increase the proportion of TIL cells except for CD4 ⁺CD25⁺Foxp3⁺ regulatory T cells (Treg), can reduce the proportion of CD4 ⁺CD25⁺Foxp3⁺ regulatory T cells (Treg), The proportion of activated T cells can be increased, the proportion of CD103 ⁺CD39⁺ tumor-specific T cells can be increased, and the proportion of TCF1 ⁺ stem cell-like T cells can be increased. As another example, altering the proportion of TIL cells according to the application may comprise increasing the proportion of CD45RO ⁺CD62L⁺ central memory T cells (Tcm) in the TIL. For example, the ratio of activated T cells that can be increased includes a member selected from the group consisting of: increasing the proportion of PD1 ⁺ cells, increasing the proportion of LAG3 ⁺ cells, and increasing the proportion of CD28 ⁺ cells. The altering the proportion of TIL cells may include increasing the proportion of central memory T cells, the proportion of activated T cells, the proportion of tumor-specific T cells, and/or the proportion of stem cell-like T cells in TIL cells cultured by the methods of the application by at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about, At least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or at least about 99%. The altering the proportion of TIL cells may include reducing regulatory T cells (tregs) in TIL cells cultured according to the methods of the application by at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or at least about 99%.

In one embodiment, the TIL may be co-cultured with feeder cells after contact with a T cell co-stimulatory molecule and/or a T cell growth factor. In one embodiment, the post may refer to more than 2 hours thereafter. For example, the TIL may be co-cultured with feeder cells after 6 to 72 hours, or 12 to 48 hours, of contact with the T cell co-stimulatory molecules and/or T cell growth factors. For example, the TIL may be co-cultured with the feeder cells after about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, or about 72 hours of contact with the T cell co-stimulatory molecule and/or T cell growth factor. For example, the TIL may be co-cultured with the feeder cells after about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days of contact with the T cell costimulatory molecules and/or T cell growth factors.

In one embodiment, the TIL may be co-cultured with feeder cells after contact with a T cell co-stimulatory molecule and/or a T cell growth factor. In one embodiment, the T cell costimulatory molecule may be selected from one or more of the following group: CD80, CD86, B7-H3, 4-1BBL, CD27, CD30, CD134, B7H, CD40, LIGHT, antibodies that specifically bind CD3, antibodies that specifically bind CD28, antibodies that specifically bind HVEM, antibodies that specifically bind CD40L, antibodies that specifically bind OX40, and antibodies that specifically bind 4-1 BB.

In one embodiment, contacting the TIL with a T cell costimulatory molecule may comprise contacting one or more of the T cell costimulatory molecules with the TIL alone and/or contacting a plurality of the T cell costimulatory molecules with the TIL simultaneously. In one embodiment, one or more of the T cell costimulatory molecules may be included in separate contact with the TIL. In one embodiment, it may be included that a plurality of the T cell costimulatory molecules are contacted with the TIL simultaneously. For example, one or more of the T cell costimulatory molecules may be added separately to the cell culture medium of the TIL, e.g., a plurality of the T cell costimulatory molecules may be added simultaneously to the cell culture medium of the TIL. For example, one of the T cell costimulatory molecules may be added to the cell culture medium of the TIL in one or more of the following groups: an engineered cell expressing the T cell costimulatory molecule, a nanoparticle chimeric to the T cell costimulatory molecule, and a polymer chimeric to the T cell costimulatory molecule. For example, a plurality of the T cell costimulatory molecules may be added to the cell culture medium of the TIL in a form selected from the group consisting of: mixtures, fusion proteins, engineered cells expressing a plurality of said T cell costimulatory molecules, nanoparticles chimeric to a plurality of said T cell costimulatory molecules, and polymers chimeric to a plurality of said T cell costimulatory molecules. For example, the T cell costimulatory molecule may be an antibody that specifically binds to CD3, e.g. OKT3 of Miltenyi Biotech.

In one embodiment, the TIL may be co-cultured with feeder cells after contact with a T cell co-stimulatory molecule and/or a T cell growth factor. In one embodiment, the T cell growth factor may be selected from one or more of the following group: IL-2, IL-4, IL-7, IL-10, IL-12, IL-15, and gamma interferon. For example, the T cell growth factor may be IL-2. In one embodiment, the initial concentration of IL-2 in the cell culture medium of the TIL may be about 1000IU/mL or more. In one embodiment, the initial concentration of the IL-2 in the cell culture medium of the TIL may be about 1500IU/mL, about 2000IU/mL, about 2500IU/mL, about 2600IU/mL, about 2700IU/mL, about 2800IU/mL, about 2900IU/mL, about 3000IU/mL, about 3100IU/mL, about 3200IU/mL, about 3300IU/mL, about 3400IU/mL, about 3500IU/mL, about 4000IU/mL, about 4500IU/mL, about 5000IU/mL, about 5500IU/mL, about 6000IU/mL, about 6500IU/mL, about 7000IU/mL, about 7500IU/mL, about 8000IU/mL, about 8500IU/mL, or about 9000 IU/mL.

In one embodiment, contacting the TIL with a T cell growth factor may include contacting one or more of the T cell growth factors with the TIL alone and/or contacting a plurality of the T cell growth factors with the TIL simultaneously. In one embodiment, one or more of the T cell growth factors may be included in separate contact with the TIL. In one embodiment, it may be included that a plurality of the T cell growth factors are contacted with the TIL simultaneously. For example, one or more of the T cell growth factors may be added separately to the cell culture medium of the TIL, e.g., multiple T cell growth factors may be added simultaneously to the cell culture medium of the TIL. For example, one of the T cell growth factors may be added to the cell culture medium of the TIL in one or more of the following forms: an engineered cell expressing the T cell growth factor, a nanoparticle chimeric to the T cell growth factor, and a polymer chimeric to the T cell growth factor. For example, a plurality of the T cell growth factors may be added to the cell culture medium of the TIL in a form selected from the group consisting of: mixtures, fusion proteins, engineered cells expressing a plurality of said T cell growth factors, nanoparticles chimeric to a plurality of said T cell growth factors, and polymers chimeric to a plurality of said T cell growth factors.

In one embodiment, the TIL may be selected from the group consisting of: TIL from fragments of tumor tissue, TIL from fragments of lymphatic metastases, TIL from pleural effusion, TIL from peritoneal effusion, TIL from tumor resection, TIL from biopsy and TIL from resuscitation after cryopreservation. In one embodiment, the TIL may be obtained by treating tumor tissue into tumor fragments. In one embodiment, the tumor fragments have a volume of about 1 to 27 cubic millimeters. In one embodiment, the tumor fragments have a volume of about 1 cubic millimeter, about 2 cubic millimeters, about 3 cubic millimeters, about 4 cubic millimeters, about 5 cubic millimeters, about 6 cubic millimeters, about 7 cubic millimeters, about 8 cubic millimeters, about 9 cubic millimeters, about 10 cubic millimeters, about 11 cubic millimeters, about 12 cubic millimeters, about 13 cubic millimeters, about 15 cubic millimeters, about 17 cubic millimeters, about 19 cubic millimeters, about 20 cubic millimeters, about 21 cubic millimeters, about 23 cubic millimeters, about 24 cubic millimeters, about 25 cubic millimeters, about 26 cubic millimeters, or 27 cubic millimeters.

In one embodiment, the feeder cells can include antigen presenting cells. In one embodiment, the feeder cells may comprise one or more selected from the group consisting of: peripheral mononuclear cells, dendritic cells, and artificial antigen presenting cells. For example, the feeder cells may be peripheral mononuclear cells. For example, the feeder cells may be dendritic cells. For example, the feeder cells may be artificial antigen presenting cells. For example, the feeder cells may be isolated artificial antigen presenting cells (aapcs) that may comprise cells expressing HLA-A/B/C, CD, CD80, ICOS-L, and CD58, and may be modified to express more than one costimulatory molecule. In one embodiment, the feeder cells may be irradiated. For example, gamma radiation may be passed, or X-ray radiation may be passed.

In one embodiment, the TIL may be co-cultured with feeder cells. In one embodiment, the co-culture may be a contact between the TIL and the surface of the feeder cells, e.g., the feeder cells may be added to the cell culture medium of the TIL. In one embodiment, the co-culture may be a contact between the TIL and the surface of the feeder cells. In one embodiment, the feeder cells may be fixed on a device and added to the cell culture medium of the TIL. In one embodiment, the feeder cells may be separated from the cells of the TIL by a membrane, mesh, grid, but may be mass exchanged or may be contacted to some extent. In one embodiment, the cellular metabolites of the feeder cells may be added to the cell culture medium of the TIL. For example, the present application may be added to the cell culture medium of the TIL of the present application in a ratio of about 40:1 to about 400:1 of the present application feeder cells to the TIL of the present application described above. For example, the present application may add the present application feeder cells to the present application's cell culture medium at a ratio of about 40:1 to about 400:1, about 40:1 to about 300:1, about 40:1 to about 200:1, about 40:1 to about 100:1, about 40:1 to about 90:1, about 40:1 to about 80:1, about 40:1 to about 70:1, about 40:1 to about 60:1, about 40:1 to about 50:1, about 50:1 to about 400:1, about 60:1 to about 400:1, about 70:1 to about 400:1, about 80:1 to about 400:1, about 90:1 to about 400:1, about 100:1 to about 400:1, about 200:1 to about 400:1, or about 300:1 to about 400:1 to the present application's TIL.

In one aspect, the application provides a method of culturing a TIL for use. The TIL cells obtained from a tissue sample of a subject may be obtained by surgical retrieval of an in situ tumor sample or a metastatic tumor sample from the patient, and may weigh at least about 1g, or may be pooled from multiple tissues. Tumor tissue is transported in basal medium at about 2-8 degrees and treated within 48 hours. The tissue pieces may be mechanically disrupted to a size of about 1-27 cubic millimeters per piece, transferred into an air-permeable culture bag or Grex, and cultured for about 3-14 days with the addition of T-cell serum-free medium and IL-2 at a concentration of 1000-9000IU/mL (which may be 6000IU/mL, for example). Cells in the culture medium are collected, can be transferred into a breathable culture bag together with a tissue block, or Grex or Xuri equipment, and the T cell serum-free culture medium can be added with CD3 antibody of about 30ng/mL, IL-2 (1000-9000 IU/mL), irradiated PBMC (TIL and PBMC are added according to the ratio of 1:40-1:400) after a certain period of activation, and are amplified and cultured for about 3-14 days. The tissue mass is filtered and cells in the culture medium can be collected using a cell handling system, washed, frozen, and detected. The CD3 ratio of the final product may be greater than 80%, the cell viability may be greater than 70%, and greater than 80% of the T cells may be memory effector T cells and effector T cells. Ifnγ can be secreted after stimulation, and can be characterized by an upregulation of the proportion of activated T cells.

In one aspect, the application provides a tumor-infiltrating lymphocyte (TIL) that can be cultured according to the culture methods of the application. In one embodiment, the TIL provided by the application may comprise one or a batch of the culture method of the application for culturing to obtain the TIL. In one embodiment, the TIL provided by the present application may comprise TIL cultured by the culture method of the present application in a plurality of or more batches and combined in any ratio.

In some embodiments, TIL amplified using the methods of the application may be administered to a patient as a pharmaceutical composition. In some embodiments, the pharmaceutical composition may be a suspension of TIL in a sterile buffer. TIL amplified using PBMCs of the application may be administered by any suitable route known in the art. In some embodiments, T cells may be administered in a single intra-arterial or intravenous infusion, which may last about 30 to 60 minutes. Other suitable routes of administration may include intraperitoneal, intrathecal and intralymphatic administration.

Any suitable dose of TIL may be administered. In some embodiments, for example when treating a tumor, about 2.3X10 ⁹ to about 13.7X10 ¹⁰ TILs may be administered. In some embodiments, about 1×10 ⁹ to about 12×10 ¹⁰ TILs may be administered. in some embodiments, about 1.2×10 ¹⁰ to about 4.3×10 ¹⁰ TILs may be administered. In some embodiments, about 3 x 10 ¹⁰ to about 12 x 10 ¹⁰ TILs may be administered. In some embodiments, about 4 x 10 ¹⁰ to about 10 x 10 ¹⁰ TILs may be administered. In some embodiments, about 5 x 10 ¹⁰ to about 8 x 10 ¹⁰ TILs may be administered. In some embodiments, about 6 x 10 ¹⁰ to about 8 x 10 ¹⁰ TILs may be administered. In some embodiments, about 7 x 10 ¹⁰ to about 8 x 10 ¹⁰ TILs may be administered. In some embodiments, a therapeutically effective dose may be from about 2.3 x 10 ⁹ to about 13.7 x 10 ¹⁰. In some embodiments, a therapeutically effective dose may be about 1 x 10 ⁹ to about 12 x 10 ¹⁰ TILs. In some embodiments, a therapeutically effective dose may be about 1.2 x 10 ¹⁰ to about 4.3 x 10 ¹⁰ TILs. In some embodiments, a therapeutically effective dose may be about 3 x 10 ¹⁰ to about 12 x 10 ¹⁰ TILs. In some embodiments, a therapeutically effective dose may be about 4 x 10 ¹⁰ to about 10 x 10 ¹⁰ TILs. In some embodiments, a therapeutically effective dose may be about 5 x 10 ¹⁰ to about 8 x 10 ¹⁰ TILs. In some embodiments, a therapeutically effective dose may be about 6 x 10 ¹⁰ to about 8 x 10 ¹⁰ TILs. In some embodiments, a therapeutically effective dose may be about 7 x 10 ¹⁰ to about 8 x 10 ¹⁰ TILs.

In some embodiments, the amount of TIL provided in the compositions of the present application may be about 1X 10 ⁶, about 2X 10 ⁶, about 3X 10 ⁶, about 4X 10 ⁶, About 5X 10 ⁶, about 6X 10 ⁶, about 7X 10 ⁶, about 8X 10 ⁶, about 9X 10 ⁶, About 1X 10 ⁷, about 2X 10 ⁷, about 3X 10 ⁷, about 4X 10 ⁷, about 5X 10 ⁷, About 6X 10 ⁷, about 7X 10 ⁷, about 8X 10 ⁷, about 9X 10 ⁷, about 1X 10 ⁸, About 2X 10 ⁸, about 3X 10 ⁸, about 4X 10 ⁸, about 5X 10 ⁸, about 6X 10 ⁸, About 7X 10 ⁸, about 8X 10 ⁸, about 9X 10 ⁸, about 1X 10 ⁹, about 2X 10 ⁹, About 3X 10 ⁹, about 4X 10 ⁹, about 5X 10 ⁹, about 6X 10 ⁹, about 7X 10 ⁹, About 8X 10 ⁹, about 9X 10 ⁹, about 1X 10 ¹⁰, about 2X 10 ¹⁰, about 3X 10 ¹⁰, About 4X 10 ¹⁰, about 5X 10 ¹⁰, about 6X 10 ¹⁰, about 7X 10 ¹⁰, about 8X 10 ¹⁰, About 9X 10 ¹⁰, about 1X 10 ¹¹, about 2X 10 ¹¹, about 3X 10 ¹¹, about 4X 10 ¹¹, About 5X 10 ¹¹, about 6X 10 ¹¹, about 7X 10 ¹¹, about 8X 10 ¹¹, about 9X 10 ¹¹, About 1X 10 ¹², about 2X 10 ¹², about 3X 10 ¹², about 4X 10 ¹², about 5X 10 ¹², About 6X 10 ¹², about 7X 10 ¹², about 8X 10 ¹², about 9X 10 ¹², about 1X 10 ¹³, About 2X 10 ¹³, about 3X 10 ¹³, about 4X 10 ¹³, about 5X 10 ¹³, about 6X 10 ¹³, About 7×10 ¹³, about 8×10 ¹³, or about 9×10 ¹³. In some embodiments, the amount of TIL provided in the compositions of the present application may range from about 1X 10 ⁶ to 5X 10 ⁶, from about 5X 10 ⁶ to 1X 10 ⁷, About 1X 10 ⁷ to 5X 10 ⁷, about 5X 10 ⁷ to 1X 10 ⁸, about 1X 10 ⁸ to 5X 10 ⁸, About 5X 10 ⁸ to 1X 10 ⁹, about 1X 10 ⁹ to 5X 10 ⁹, about 5X 10 ⁹ to 1X 10 ¹⁰, about 1X 10 ¹⁰ to 5X 10 ¹⁰, about 5X 10 ¹⁰ to 1X 10 ¹¹, about 5X 10 ¹¹ to 1X 10 ¹², About 1×10 ¹² to 5×10 ¹², or about 5×10 ¹² to 1×10 ¹³.

In some embodiments, the concentration of TIL provided in the compositions of the present application may be less than, for example, about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 19%, about 18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, about 0.1%, about 0.09%, about 0.08%, about 0.07%, about 0.06%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, about 0.01%, about 0.009%, about 0.008%, about 0.007%, about 0.006%, about 0.005%, about 0.002%, about 0.003%, about 0.002%, about 0.001%, about 0.0009%, about 7%, about 0.0008%, about 0.0006%, about 0.004%, about 0.0006% w/0006%, or about 0.0003% w/0000.0006% w/w of the composition.

In some embodiments of the present application, in some embodiments, the concentration of TIL provided in the compositions of the present application may be greater than about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 19.75%, about 19.50%, about 19.25%, about 19%, about 18.75%, about 18.50%, about 18.25%, about 18.75%, about 17.50%, about 17.25%, about 17%, about 16.75%, about 16.50%, about 16.25%, about 16%, about 15.75%, about 15.50%, about 15.25%, about 15%, about 14.75%, about 14.50%, about 14.25%, about 14%, about 13.75%, about 13.50%, about 13.25%, about 12.75%, about 12.50%, about 12.25%, about 12%, about 11.75%, about 11.50%, about 10.25%, about 10.75%, about 9.75%, about 9.50%, about 9.25%, about 8%, about 8.25% of the composition. About 8%, about 7.75%, about 7.50%, about 7.25%, about 7%, about 6.75%, about 6.50%, about 6.25%, about 6%, about 5.75%, about 5.50%, about 5.25%, about 5%, about 4.75%, about 4.50%, about 4.25%, about 4%, about 3.75%, about 3.50%, about 3.25%, about 3%, about 2.75%, about 2.50%, about 2.25%, about 2%, about 1.75%, about 1.50%, about 125%, about 1%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, about 0.1%, about 0.09%, about 0.08%, about 0.07%, about 0.06%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, about 0.01%, about 0.009%, about 0.008%, about 0.007%, about 0.006%, about 0.005%, about 0.004%, about 0.003%, about 0.001%, about 0.0000.0008%, about 3%, about 0.0000.0000.0008%, or about 0.0001% w/w, w/v or v/v.

In some embodiments, the concentration of TIL provided in the compositions of the present application may range from about 0.0001% to about 50%, from about 0.001% to about 40%, from about 0.01% to about 30%, from about 0.02% to about 29%, from about 0.03% to about 28%, from about 0.04% to about 27%, from about 0.05% to about 26%, from about 0.06% to about 25%, from about 0.07% to about 24%, from about 0.08% to about 23%, from about 0.09% to about 22%, from about 0.1% to about 21%, from about 0.2% to about 20%, from about 0.3% to about 19%, from about 0.4% to about 18%, from about 0.5% to about 17%, from about 0.6% to about 16%, from about 0.7% to about 15%, from about 0.8% to about 14%, from about 0.9% to about 12%, or from about 1% to about 10% w/v or v/v of the composition.

In some embodiments, the concentration of TIL provided in the compositions of the present application may range from about 0.001% to about 10%, from about 0.01% to about 5%, from about 0.02% to about 4.5%, from about 0.03% to about 4%, from about 0.04% to about 3.5%, from about 0.05% to about 3%, from about 0.06% to about 2.5%, from about 0.07% to about 2%, from about 0.08% to about 1.5%, from about 0.09% to about 1%, or from about 0.1% to about 0.9% w/w, w/v, or v/v of the composition.

In some embodiments of the present application, in some embodiments, the amount of TIL provided in the compositions of the present application may be equal to or less than about 10g, about 9.5g, about 9.0g, about 8.5g, about 8.0g, about 7.5g, about 7.0g, about 6.5g, about 6.0g, about 5.5g, about 5.0g, about 4.5g, about 4.0g, about 3.5g, about 3.0g, about 2.5g, about 2.0g, about 1.5g, about 1.0g, about 0.95g, about 0.9g, about 0.85g, about 0.8g, about 0.75g, about 0.7g, about 0.65g, about 0.6g, about 0.55g, about 0.5g, about 0.45g, about 0.4g, about 0.35g, about 0.3g, about 0.25g, about 0.2g, about 15g, about 1.03 g, about 08g, about 0.09g, about 0.02g, about 0.001g, about 0.0003g, about 0.001g, about 0.0000.04 g, about 0.01g, about 0.0008g, about 0.04g, about 0.01 g.

In some embodiments of the present application, in some embodiments, the amount of TIL provided in the compositions of the present application may be greater than about 0.0001g, about 0.0002g, about 0.0003g, about 0.0004g, about 0.0005g, about 0.0006g, about 0.0007g, about 0.0008g, about 0.0009g, about 0.001g, about 0.0015g, about 0.002g, about 0.0025g, about 0.003g, about 0.0035g, about 0.004g, about 0.0045g, about 0.005g, about 0.0055g, about 0.006g, about 0.0065g, about 0.007g, about 0.0075g, about 0.008g, about 0.0085g, about 0.009g, about 0.0095g, about 0.01g, about 0.015g, about 0.02g, about 0.025g, about 0.03g, about 0.035g, about 0.04g, about 0.006g about 0.05g, about 0.055g, about 0.06g, about 0.065g, about 0.07g, about 0.075g, about 0.08g, about 0.085g, about 0.09g, about 0.095g, about 0.1g, about 0.15g, about 0.2g, about 0.25g, about 0.3g, about 0.35g, about 0.4g, about 0.45g, about 0.5g, about 0.55g, about 0.6g, about 0.65g, about 0.7g, about 0.75g, about 0.8g, about 0.85g, about 0.9g, about 0.95g, about 1g, about 1.5g, about 2g, about 2.5g, about 3g, about 4g, about 4.5g, about 5.5g, about 6g, about 6.5g, about 7.7 g, about 7.5g, about 8g, about 9g, about 5g, about 9g, or about 10g.

In some embodiments, the TIL may be administered in a single dose. Such administration may be by injection, for example intravenous injection. In some embodiments, the TIL may be administered in multiple doses. The dosage may be once, twice, three times, four times, five times, six times or more than six times per year. The dosage may be monthly, biweekly, weekly or every 2 days. In some embodiments, the administration of the TIL may be continuous.

In another aspect, the application provides a method of culturing the TIL used. The TIL cells obtained from a tissue sample of a subject may be obtained by surgical retrieval of an in situ tumor sample or a metastatic tumor sample from the patient, and may weigh at least about 1g, or may be pooled from multiple tissues. Tumor tissue is transported in a sample transport solution, such as a commercially available tumor tissue transport solution, a tumor tissue preservation solution or a tumor tissue transport solution, at about 2-8 degrees, and is processed within 48 hours. The tissue pieces may be mechanically disrupted to a size of about 1-27 cubic millimeters per piece, transferred into a gas-permeable culture bag or Grex, and cultured for about 3-14 days with the addition of T-cell serum-free medium and IL-2 at a concentration of 300-9000IU/mL (which may be, for example, 1000-9000IU/mL, which may be, for example, 6000 IU/mL). The harvested TIL cells may be thawed and then resuscitated, or the cells in the culture medium may be directly collected, transferred into a permeable culture bag, or Grex, or Xuri device, and the T cell serum-free medium may be supplemented with the CD3 antibody of the present application, IL-2 at a concentration of 300 to 9000IU/mL (for example, 1000 to 9000IU/mL, for example, 6000 IU/mL), activated for a certain period of time, irradiated PBMC (TIL to PBMC at a ratio of about 1:40 to about 1:400) and expanded and cultured for about 3 to 14 days. Cells in the medium can be collected, washed, frozen, and detected using a cell handling system. The CD3 ratio of the final product may be greater than 80%, the cell viability may be greater than 50%, and greater than 80% of the T cells may be memory effector T cells and effector T cells. IFN-gamma may be secreted upon stimulation and/or may be characterized by an upregulation of the proportion of activated T cells.

In one aspect, the application provides a pharmaceutical formulation. In some embodiments, it may comprise the TIL of the present application and/or the composition of the present application, together with a pharmaceutically acceptable carrier.

In one aspect, the application provides a pharmaceutical composition, which may comprise a TIL obtained according to the culture method described in the application of the application, together with a substance which may reduce the number of lymphocytes and/or a substance which may maintain the proliferative capacity of said TIL.

In one aspect, the application provides a pharmaceutical composition that may comprise cyclophosphamide and/or fludarabine.

In one aspect, the application provides a pharmaceutical composition that may comprise interleukin-2 (IL-2) or a variant thereof.

For example, the cyclophosphamide may be included at a dose of about 300 to about 500mg/m ²/day. Cyclophosphamide may be included at a dose of about 50mg/m ²/day, about 100mg/m ²/day, about 150mg/m ²/day, about 200mg/m ²/day, about 250mg/m ²/day, about 300mg/m ²/day, about 350mg/m ²/day, about 400mg/m ²/day, about 450mg/m ²/day, or about 500mg/m ²/day.

For example, the fludarabine may be included at a dose of about 20 to about 30mg/m ²/day. For example, fludarabine may be included at a dose of about 5mg/m ²/day, about 10mg/m ²/day, about 15mg/m ²/day, about 20mg/m ²/day, about 25mg/m ²/day, or about 30mg/m ²/day.

For example, the IL-2 may be included at a dose of about 200,000 to about 600,000IU/kg/dose. IL-2 may be included at a dose of about 100,000 IU/kg/time, about 200,000 IU/kg/time, about 300,000IU/kg/time, about 400,000IU/kg/time, about 500,000 IU/kg/time, or about 600,000IU/kg/time.

In one aspect, the application provides a kit, which may comprise a pharmaceutical composition according to the application.

In one aspect, the application provides a kit that may comprise a T cell costimulatory molecule, a T cell growth factor, and/or a feeder cell according to the method of culturing tumor-infiltrating lymphocytes (TILs) of the application together with instructions describing the steps of the method of culturing tumor-infiltrating lymphocytes (TILs) of the application. In one aspect, the application provides a kit that may comprise the TIL of the application and/or the pharmaceutical formulation of the application.

In one aspect, the application provides a method of affecting tumor cell growth, which may comprise administering to a subject a TIL of the application and/or a pharmaceutical formulation of the application. In some embodiments, affecting tumor growth may comprise a reduction in tumor volume to, for example, about 99%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 19%, about 18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, or about 0.1% prior to administration.

In one aspect, the application provides the use of a TIL according to the application and/or a pharmaceutical formulation according to the application for the preparation of a medicament which can be used for the prophylaxis and/or treatment of tumours. In some embodiments, the tumor is selected from a solid tumor. In some embodiments, the tumor may be selected from one or more of the following groups: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer, and renal cancer. For example, a tumor of the application may refer to an advanced solid tumor. For example, a tumor of the present application may refer to an incurable resectable solid tumor. For example, a tumor of the application may refer to a solid tumor that is recurrent and/or metastatic. For example, a tumor of the application may refer to a recurrent and/or metastatic advanced solid tumor that is not radical resectable.

In one aspect, the application provides a method of preventing and/or treating a tumor, which may comprise administering to a subject a TIL according to the application and/or a pharmaceutical formulation according to the application. In some embodiments, the tumor is selected from a solid tumor. In some embodiments, the tumor may be selected from one or more of the following groups: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer, and renal cancer. For example, a tumor of the application may refer to an advanced solid tumor. For example, a tumor of the present application may refer to an incurable resectable solid tumor. For example, a tumor of the application may refer to a solid tumor that is recurrent and/or metastatic. For example, a tumor of the application may refer to a recurrent and/or metastatic advanced solid tumor that is not radical resectable. For example, a subject of the application may meet one, more or all of the inclusion criteria of the application. For example, a subject of the application may not have one, more or all of the exclusion criteria of the application. For example, the effects of the present application can be assessed by the safety, tolerability, efficacy and/or pharmacokinetics assessments described herein. For example, subjects of the application may isolate tissue pieces (which may be of single lesion origin or multiple lesions pooled) having a volume of ≡0.5cm ³ for use in the preparation of autologous tumor infiltrating lymphocytes.

In one aspect, the present application provides a TIL according to the present application and/or a pharmaceutical formulation according to the present application, which may be used for the prevention and/or treatment of tumors. In some embodiments, the tumor is selected from a solid tumor. In some embodiments, the tumor may be selected from one or more of the following groups: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer, and renal cancer. For example, a tumor of the application may refer to an advanced solid tumor. For example, a tumor of the present application may refer to an incurable resectable solid tumor. For example, a tumor of the application may refer to a solid tumor that is recurrent and/or metastatic. For example, a tumor of the application may refer to a recurrent and/or metastatic advanced solid tumor that is not radical resectable.

Without intending to be limited by any theory, the following examples are meant to illustrate the methods and uses of the present application and the like and are not intended to limit the scope of the application.

Examples

EXAMPLE 1 method for culturing tumor-infiltrating lymphocyte (TIL) cells

1.1 Feeder cell reception and preparation

1.1.1 Single blood sampling reception

The apheresis information, lot number and volume were recorded and rewarmed to room temperature.

1.1.2PBMC (peripheral blood mononuclear cells) manual separation and cryopreservation

The bags were sterilized with 75% alcohol and transferred to a biosafety cabinet. After the blood bag was cut with sterile scissors, the single blood sample was transferred into a 50mL centrifuge tube, and the blood bag was washed with 20mL PBS or physiological saline by injecting the washing solution into the 50mL centrifuge tube. The liquid volume in each 50mL centrifuge tube may not exceed 30mL. The blood was collected by centrifugation at 3000g for 10 minutes. During the centrifugation, 6-8 50mL centrifuge tubes were prepared, and the re-warmed lymphocyte separation liquid (Tianjin ocean Ficoll) was added at 20 mL/min. After centrifugation, the upper plasma layer is discarded, the cell pellet is diluted by PBS or physiological saline, and the diluted blood cell mixture is slowly dripped on the upper layer of lymphocyte separation liquid, so that the interface is not destroyed, and 25mL of sample can be added in each tube, and the volume of sample can be not more than 28mL.

The horizontal rotor is used for centrifugation, 500-600g is used for centrifugation for 15-30 minutes, the temperature is 18-22 ℃, and the white membrane layer obtained after the centrifugation is finished is positioned at the interface of normal saline and Ficoll. The upper plasma and saline were pipetted off and the middle buffy coat was pipetted into another clean 50mL centrifuge tube. The collected white film layer was diluted with PBS or physiological saline, and centrifuged at 600g for 10 minutes at room temperature. After centrifugation, the supernatant was discarded, and the cells were washed once with PBS or physiological saline, and centrifuged at 500g for 5 minutes at room temperature.

If more red blood cells are contained, red blood cell lysate can be added according to the volume of cell sediment and the ratio of 1:2 to 1:3 of the red blood cell lysate, the red blood cells are evenly mixed, the red blood cells are lysed for 10 minutes at room temperature, the middle part of the red blood cells are gently mixed evenly in a centrifuge tube for 2 to 3 times, the lysis effect is ensured, and PBS or physiological saline is added to clean the cells after the completion of the lysis. After the lysis, the cells were washed twice, centrifuged at 400g for 6 minutes, and counted by sampling before the last centrifugation.

Discarding the supernatant, re-suspending cells with the basic culture medium, adjusting the cell density to about 2-3×10 ⁷/mL, wherein the liquid level height can be no more than 1 cm, and the volume in each T225 culture bottle can be lower than 200mL; in the tiled state, the X-ray irradiation was 50Gy. Centrifuging to remove supernatant, and counting jelly cell according to about 1-2× ⁸/mL and 1-2 mL/branch; the cells are put into a program cooling box to be transferred to a refrigerator with the temperature of minus 80 ℃ for freezing and storing.

1.1.3 PBMC automatic separation and cryopreservation

The tubing of the blood bag is separated from cpro from the input sterile connection of the set (Cytiva). If the blood volume is greater than 120mL, the blood volume may be concentrated to within 120mL by performing a pre-concentration step. PBMC separation and washing can be performed using neatcell procedure, the washing solution is normal saline, the intermediate volume is 20mL; the resuspension was taken as basal medium and 80 mL/batch was added. After separation, each donor PBMC is 100mL, and in a flat state, the liquid level can be no more than 1 cm, and the X-ray irradiation is 50Gy. Sampling and counting after irradiation, mixing 3-5 donor PBMC suspensions according to the ratio of 0.5:1 to 1:2, collecting cells by using a culture wash program and washing three times, wherein the washing liquid is physiological saline; setting the intermediate volume and the final volume so that no less than 2mL per 1×10 ⁹ cells; adding the frozen stock solution with the equivalent amount of 2 times, and uniformly mixing. And (3) regulating the cell density to be about 1X 10 ⁷/mL to 2X 10 ⁸/mL by using 1-time frozen stock solution, subpackaging to 20 mL/bag, freezing in a program cooling instrument, and preserving in liquid nitrogen.

1.2 Tumor tissue reception and treatment

1.2.1 Tissue reception

The tumor tissue and the blood sample of the donor are received, the sample information is checked and recorded, and the corresponding sample label is printed.

1.2.2 Tissue treatment and culture

The sample tube and the blood collection tube are sterilized with 75% alcohol and transferred into a biosafety cabinet. PBMC cells in the blood samples were isolated and frozen according to the PBMC manual isolation and frozen procedures described above. A flask and bag with a gas permeable surface, such as a G-Rex100 flask (Wilson Wolf Manufacturing), is filled with 300mL of the complete medium that has been warmed, optionally with X-vivo 15 medium or other commercial T Cell medium, such as Stem Cell, lonza, thermo, meta, etc., and with the necessary amino acids and antibiotics, and IL-2, such as 6000IU/mL, is added. A plurality of 10 cm culture dishes are taken, a proper amount of culture medium is added, tumor tissues are taken out of a sample tube by using sterile ophthalmic forceps and are placed in the 10 cm culture dishes, the amount of the culture medium is based on the condition that the tumor tissues just have been soaked, and the tissue morphology is observed and recorded. The tissue was washed and the dish was replaced. Preliminary shearing is performed by using an ophthalmic shear and an ophthalmic forceps to remove adipose tissue and necrotic tissue, and each tissue block is continuously sheared to a size of about 27 cubic millimeters. After removing the internal piston from the non-suspended tumor tissue mass using a 20mL syringe, the tissue mass was connected to a culture bag, and about 1g of the tissue mass was transferred into the culture bag by a pipette through the syringe. The culture bag is placed into a carbon dioxide incubator for culture. Cleaning scissors and tweezers, performing primary disinfection by using 75% alcohol, performing ultrasonic cleaning, and performing sterilization to obtain primary TIL.

1.3 First stage amplification and harvesting

1.3.1 First stage amplification

According to the growth state of the cells, the liquid is supplemented or replaced in half every 3-7 days, so that the nutrition of the cells is ensured. As the complete medium, X-vivo 15 medium or other commercial T Cell medium such as Stem Cell, lonza, thermo, meta-Tian, etc. brand T Cell medium may be optionally used, and essential amino acids and antibiotics may be added, and IL-2, for example, IL-2 at a concentration of about 1000 to 9000IU/mL, such as 6000IU/mL, may be added. The first stage of amplification may be performed for 3-14 days, for example, by sampling and counting at days 3,4, 5, 6,7,8, 9, 10, 11, 12, 13 or 14, and the harvesting step of the first stage of amplification described below may be performed if the number of cells is between 5X 10 ⁵ and 5X 10 ⁸.

1.3.2 Harvesting of first stage amplification

Collecting the cells after the first-stage amplification, centrifuging, discarding the culture medium, washing the cells once by using PBS or physiological saline to obtain TIL amplified in the first stage, and taking a sample to count and leave about 5X 10 ⁵ to 2X 10 ⁸ cells for the following first-stage amplification step; quality control testing can be performed by taking about 5X 10 ⁵ cells; the rest cell amount is added with 2 times of equivalent frozen stock solution for freezing and preserving.

1.4 Second stage amplification

1.4.1 TIL activation of second stage amplification

The first stage of expansion of 5X 10 ⁵ to 2X 10 ⁸ is performed using complete medium, which may optionally be X-vivo 15 medium or other commercial T Cell medium, such as Stem Cell, lonza, thermo, meta, etc., and may be supplemented with the necessary amino acids and antibiotics to adjust the Cell density to 5X 10 ⁵ to 2X 10 ⁶/mL, and in suspension 24-well plates, 1 mL/well, CD3 antibody, such as OKT3, is added at about 30ng/mL, IL-2 is added at a concentration of about 1000 to 9000IU/mL, such as 6000 IU/mL.

1.4.2 Amplification of second stage amplification

In the second stage, after a period of time T _n following addition of OKT3 and IL-2 (T _n may take 0 hours to 14 days), 1-5 donor mixed feeder cells are resuscitated; transferring activated TIL cells, tissue blocks and feeder cells into G-Rex100 culture bottle or air permeable bag, supplementing complete culture medium, sampling and counting every 1-3 days, supplementing liquid or half-changing liquid according to cell state until total cell number is greater than 1×10 ⁹ or second stage amplification culture is completed for 14 days, and stopping culture.

1.4.3 Harvesting of tumor-infiltrating lymphocytes

Taking the cells amplified in the second stage, centrifuging, discarding the supernatant of the culture medium, washing for three times by using PBS (phosphate buffer solution) or normal saline or compound electrolyte solution to obtain TIL amplified in the second stage, sampling and counting in the third washing, centrifuging the supernatant of the last time according to the counting result, and taking 3X 10 ⁶ cells for quality control detection; adding the rest whole cells into the frozen stock solution, and regulating the cell density to 1-3×10 ⁸/mL for frozen stock.

1.5 Application of tumor-infiltrating lymphocytes

The resuscitated therapeutic tumor-infiltrating lymphocytes can be administered to a subject by intravenous drip.

EXAMPLE 2 comparison of proliferation potency of TIL cultured at different addition times of feeder cells

In the second stage expanded TIL activation of example 1.4, feeder cells were added to tumor-infiltrating lymphocyte culture bags after a few times T _n (T _n may take 0 hours to 14 days) following addition of OKT3 and IL-2. T _n in this example was selected from TIL cultured at different addition times for feeder cells for 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 5 days, 7 days, and 9 days, and a comparative test of cell count was performed.

Proliferation potency assays of TIL cultured at different addition times of feeder cells are shown in figure 1. The values on the ordinate in each group of figures for TIL cultured at different times of feeder cells indicate the expansion times to which the number of TIL cells was expanded after the end of the second-stage expansion compared to before the start of the second-stage expansion. Proliferation of the 4 donor-derived TILs showed that the proliferation capacity of the TILs cultured with the addition of feeder cells was weaker than that of the TILs cultured with the addition of feeder cells after 0 hours (i.e., simultaneously) after the addition of OKT3 and IL-2, and after 24 hours or after 48 hours after the addition of OKT3 and IL-2.

Example 3 comparison of TIL flow assay with feeder cells cultured at different addition times

In the second stage expanded TIL activation of example 1.4, feeder cells were added to tumor-infiltrating lymphocyte culture bags after a few times T _n (T _n may take 0 hours to 14 days) following addition of OKT3 and IL-2. T _n in this example was selected from the group consisting of 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 5 days, 7 days, and 9 days to obtain TIL for different feeder cell addition times and to conduct a comparative test for flow detection.

Sources of TIL flow detection test materials

Transcription factor buffer group (Transcription Factor Buffer Set), manufacturer BD, cat No. 562574; v-bottom 96-well plate, corning, cat# 3894; flow tube, manufacturer Corning, cat number 352052.

The example flow antibody was purchased from BD or Biolegend. Each set of 1X 10 ⁵ to 5X 10 ⁵ cell samples was added to a flow tube or V-bottom 96-well plate. Centrifuge at 600g for 3 min, discard supernatant. The PBS was washed once, the flow tube was 1 mL/tube, the 96-well plate was 250. Mu.L/well, and the supernatant was discarded. And (3) adding the prepared antibody working solution to perform cell surface staining, wherein the concentration of the antibody (BD or Biolegend) is 1:100-1:200, and the concentration of the antibody contains an active detection dye 1:10000. Flow tube 100. Mu.L/tube, 96 well plate 50. Mu.L/Kong Ranse, incubation at 2-8deg.C for 30 min protected from light. Preparing reagents required by transcription factor staining in the staining process: diluting the 4X fixed rupture of membranes liquid (BD, fixation/Permeabilization) to 1X working liquid A by using a transcription factor buffer group (BD, transcription Factor Buffer Set); diluting 5 Xpenetrating cleaning solution (BD, perm/Wash Buffer) into 1 Xworking solution B by using double distilled water, and pre-cooling for four times for standby. After the completion of staining, cells were washed 2 times with an appropriate amount of PBS (250. Mu.L/time in 96-well plates, 1 mL/time in flow tubes), centrifuged at 600g for 3 minutes, and the supernatant was discarded after centrifugation. Cell fixation and membrane rupture: the cells were resuspended thoroughly, and fixed rupture of membranes was performed by adding an appropriate amount (96-well plate 100. Mu.L/well, flow tube 1 mL/tube) of 1 Xworking solution A, and incubated at 2-8deg.C for 40-50 min in the absence of light. After the completion of the fixation and rupture of membranes, cells were washed with 1 Xworking solution B (96 well plates 250. Mu.L/time, flow tubes 2 mL/time), centrifuged at 2-8℃and centrifuged at 350g for 6 minutes, and washed twice. Intracellular antibodies were formulated using 1 Xworking solution B at antibody concentrations of 1:100 to 1:200, 96 well plates 50. Mu.L/well, flow tubes 100. Mu.L/tube, and stained at 2-8deg.C for 30 minutes in the absence of light. After the completion of staining, cells were washed with 1 Xworking solution B (96 well plate 250. Mu.L/time, flow tube 2 mL/time), centrifuged at 2-8℃and 350g for 6 minutes, and washed twice. After the surface staining was completed, the cells were washed once with PBS (96-well plate 250. Mu.L/time, flow tube 1 mL/time), centrifuged at 600g for 3 minutes at room temperature, and the supernatant was discarded after centrifugation. The cells were resuspended using 100-500. Mu.L PBS and flow-on-machine detected.

Flow results analysis of TIL cultured at different addition times of feeder cells are shown in fig. 2 to 8.

FIGS. 2 to 3 show the proportion of CD45RA ^-CCR7⁺ central memory T cells (Tcm) of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2. The results showed that the addition of feeder cells-cultured TIL after 24 hours or 48 hours had a higher proportion of central memory T cells than the simultaneous addition of feeder cells-cultured TIL.

FIG. 4 shows the proportion of CD4 ⁺CD25⁺Foxp3⁺ regulatory T cells (Treg) of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of OKT3 and IL-2 addition. The results showed that the addition of feeder cells-cultured TIL after 24 hours or 48 hours had a smaller proportion of regulatory T cells than the simultaneous addition of feeder cells-cultured TIL.

FIGS. 5 to 6 show the proportion of activated T cells of TIL cells cultured by adding feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2. The results show that the addition of feeder cells-cultured TIL after 24 hours or 48 hours has a higher proportion of activated T cells, e.g. a higher proportion of PD1 ⁺、LAG3⁺ and/or CD28 ⁺ cells, than the simultaneous addition of feeder cells-cultured TIL.

FIG. 7 shows the proportion of CD103 ⁺CD39⁺ tumor-specific T cells of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2. The results showed that the addition of feeder cells-cultured TIL after 24 hours or 48 hours had a higher proportion of tumor-specific T cells than the simultaneous addition of feeder cells-cultured TIL.

FIG. 8 shows the TCF1 ⁺ stem cell-like T cell fraction of cultured TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of OKT3 and IL-2 addition. The results showed that the addition of feeder cells-cultured TIL after 24 hours or 48 hours had a higher proportion of stem cell-like T cells than the simultaneous addition of feeder cells-cultured TIL.

EXAMPLE 4 statistics of results of TIL cultured at different addition times of feeder cells

In the second stage of the expanded TIL activation of 1.4 of example 1, the amount of the cells expanded in the first stage was adjusted to 5X 10 ⁵ to 2X 10 ⁶/mL, and a CD3 antibody, for example, OKT3, was added at a concentration of about 30ng/mL and IL-2, for example, 3000 or 6000IU/mL was added at a concentration of about 1000 to 9000IU/mL to 1 mL/well in a 24-well-suspended culture plate. After 0 hours, 24 hours, 48 hours after addition of OKT3 and IL-2 described above, feeder cells were added to the culture environment of tumor-infiltrating lymphocytes. Wherein TIL and feeder cells can be added in a ratio of 1:40 to 1:400, and all cells are collected after about 9-14 days of expansion culture in the second stage, and the results of the TIL obtained by the culture are detected and counted.

Proliferation potency assay

Cell counts were performed for TIL obtained by culturing the above feeder cells at different addition times.

TIL from different donor tumor sources as respective different batches; data from each of the test groups to which OKT3 and IL-2 were added simultaneously (0 h group) to feeder cells were used as reference 1, data from the other time-point test groups of the same batch were normalized, and the relative proliferation capacity of each test group was counted for the second stage of amplification relative to the 0h group.

FIG. 9 shows the results of the cell proliferation capacity of TIL cells cultured by adding feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2. The proliferation capacity of TIL cultured with feeder cells was significantly enhanced 24 hours or 48 hours after addition of OKT3 and IL-2 compared to TIL cultured with feeder cells after 0 hours (i.e., at the same time) after addition of OKT3 and IL-2.

Flow assay for TIL cell composition

Flow assays were performed on TIL populations obtained from the above feeder cells cultured at different addition times.

TIL from different donor tumor sources as respective different batches; data from each of the test groups to which OKT3 and IL-2 were added simultaneously (0 h group) to feeder cells were used as reference 1, data from the test groups at other time points of the same batch were normalized, and the proportion of cell composition in the second stage of expansion was counted for each test group relative to the 0h group.

The flow test procedure of the flow test can be referred to in the content of embodiment 3 of the present application.

FIG. 10 shows a graph of the results of the proportion of CD45RA ^-CCR7⁺ central memory T cells (Tcm) of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours, or 48 hours of OKT3 and IL-2 addition. The results showed that the addition of feeder cells-cultured TIL after 24 hours or 48 hours had a higher proportion of central memory T cells in CD8 ⁺ and/or in CD4 ⁺ than the simultaneous addition of feeder cells-cultured TIL.

FIG. 11 shows the TCF1 ⁺ stem cell-like T cell fraction of cultured TIL cells, cultured with the addition of feeder cells 0 hours, 24 hours or 48 hours after the addition of OKT3 and IL-2. The results showed that the addition of feeder cells-cultured TIL after 24 hours or 48 hours had a higher proportion of stem cell-like T cells in CD8 ⁺ than the simultaneous addition of feeder cells-cultured TIL.

FIG. 12 shows the proportion of CD4 ⁺CD25⁺Foxp3⁺ regulatory T cells (Treg) of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of OKT3 and IL-2 addition. The results showed that the addition of feeder cells-cultured TIL after 24 hours or 48 hours had a smaller proportion of regulatory T cells than the simultaneous addition of feeder cells-cultured TIL.

FIG. 13 shows the proportion of activated T cells (PD 1 ⁺) of TIL cells cultured by adding feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2. The results show that the addition of feeder cells-cultured TIL after 24 hours or 48 hours has a higher proportion of activated T cells, e.g. a higher proportion of PD1 ⁺ cells in CD8 ⁺ and/or CD4 ⁺, than the simultaneous addition of feeder cells-cultured TIL.

FIG. 14 shows the proportion of CD103 ⁺CD39⁺ tumor-specific T cells of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2. The results showed that the addition of feeder cells-cultured TIL after 24 hours or 48 hours had a higher proportion of tumor-specific T cells in CD8 ⁺ and/or in CD4 ⁺ than the simultaneous addition of feeder cells-cultured TIL.

FIG. 15 shows the proportion of activated T cells (CD 28 ⁺) of TIL cells cultured by adding feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2. The results show that the addition of feeder cells-cultured TIL after 24 hours or 48 hours has a higher proportion of activated T cells, e.g., a higher proportion of CD8 ⁺CD28⁺ cells, than the simultaneous addition of feeder cells-cultured TIL.

FIG. 16 shows the proportion of activated T cells (41 BB ⁺) of TIL cells cultured by adding feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2. The results show that the addition of feeder cells-cultured TIL after 24 hours or 48 hours has a higher proportion of activated T cells, e.g. 41BB ⁺ cells in CD8 ⁺ and/or CD4 ⁺, than the simultaneous addition of feeder cells-cultured TIL.

FIG. 17 shows the proportion of activated T cells (CD 25 ⁺) of TIL cells cultured by adding feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2. The results show that the addition of feeder cells-cultured TIL after 24 hours or 48 hours has a higher proportion of activated T cells, e.g. a higher proportion of CD25 ⁺ cells in CD8 ⁺ and/or CD4 ⁺, than the simultaneous addition of feeder cells-cultured TIL.

Intracellular factor expression detection

Test preparation

Preparing a culture medium required for intracellular factor expression detection: t cell culture medium was taken and CD107a antibody (BD) was added at a volume ratio of 1:500.

Detection step

After TIL centrifugation of each test group, 1X 10 ⁶ cells/mL was resuspended in 600. Mu.L of the above medium required for intracellular factor expression detection, added to 96-well plates, 100. Mu.L/well, and incubated overnight in a 37℃incubator.

After the incubation was completed, 200. Mu.L/well PBS was washed once, centrifuged at 600g for 3 minutes, and the supernatant was discarded. The mixed working solution of the antibodies is prepared for cell surface staining CD3/CD4/CD8 (BD), the concentration of the antibodies is 1:100, the concentration of the antibodies is virability (1:10000), 50 mu L/group staining is carried out, and the cells are incubated for 30 minutes at 2-8 ℃ in a dark place. After staining, cells were washed and resuspended in PBS for flow-on-machine detection.

FIG. 18 shows the results of intracellular factor expression detection of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2. The results showed that the addition of feeder cells-cultured TIL after 24 hours or 48 hours had a higher intracellular factor expression capacity than the simultaneous addition of feeder cells-cultured TIL. For example, higher CD107a expression capacity in CD3 ⁺, in CD8 ⁺ and/or in CD4 ⁺.

Cytokine secretion assay

The cytokine secretion detection method can refer to the instruction of a cytokine detection kit (BD), the human Th1/Th2/Th17 cytokine standard lyophilized powder (BD) is reconstituted with 2mL Assay reagent Diluent (BD) (the concentration of each cytokine in standard stock solution is 5000 pg/mL) and the following steps are performed: 1:2,1:4,1:8,1:16,1:32,1:64,1:128,1:256,1:512,1:1024 gradient dilution, labeled "standard tube". Take 1 tube containing Assay Diluent dilution alone as reference. Each Capture Beads (BD) was added at 2. Mu.L/Beads/well, then PE Detection Reagent detection reagent (BD) was added at 10. Mu.L/well and mixed to prepare a mixture (mix), 22. Mu.L/well was added to a V-bottom 96-well plate, and then the supernatants of each standard and test group were added at 10. Mu.L/well and mixed, and incubated at room temperature in the absence of light for 3 hours.

At the end of incubation, 200. Mu.L Wash Buffer (BD) was added to each well and centrifuged at 500g for 3 min. At the end of centrifugation, 100. Mu.L Wash Buffer (BD) was added to each well for resuspension and flow analysis.

FIG. 19 shows the results of cytokine secretion assays of TIL cells cultured with the addition of feeder cells after 0 hours, 24 hours or 48 hours of addition of OKT3 and IL-2. The results showed that the addition of feeder cells-cultured TIL after 24 hours or 48 hours had a higher cytokine secretion capacity than the simultaneous addition of feeder cells-cultured TIL. For example, a higher TNF- α secretion capacity, or a higher IFN- γ secretion capacity.

EXAMPLE 5 statistics of results of TIL cultured at different addition times of feeder cells

In the second stage of the expanded TIL activation of 1.4 of example 1, the amount of the cells expanded in the first stage was adjusted to 5X 10 ⁵ to 2X 10 ⁶/mL, and a CD3 antibody, for example, OKT3, was added at a concentration of about 30ng/mL and IL-2, for example, 3000 or 6000IU/mL was added at a concentration of about 1000 to 9000IU/mL to 1 mL/well in a 24-well-suspended culture plate. After 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or 5 days after addition of OKT3 and IL-2 described above, feeder cells were added to the culture environment of tumor-infiltrating lymphocytes. Wherein TIL and feeder cells may be added in a ratio of 1:40 to 1:400, e.g., 1:200, and all cells collected after about 9-14 days of second stage expansion culture, and the results of culturing the resulting TIL are detected and counted.

Proliferation potency assay

FIG. 20 shows graphs of results of cell proliferation capacity of TIL cells obtained by culturing TIL cells after 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or 5 days of addition of OKT3 and IL-2. The proliferation capacity of TIL in feeder cell culture after 12 hours or more after addition of OKT3 and IL-2 was significantly enhanced compared to TIL in feeder cell culture after 0 hours (i.e., at the same time) after addition of OKT3 and IL-2.

Flow assay for TIL cell composition

FIG. 21 shows the CD8 ⁺ T cell fraction of TIL cells cultured after 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or 5 days of addition of OKT3 and IL-2. The results showed that the addition of feeder cells-cultured TIL after 12 hours or more after the addition of OKT3 and IL-2 had a higher proportion of CD8 ⁺ T cells than the simultaneous addition of feeder cells-cultured TIL.

FIG. 22 shows the proportion of CD45RO ⁺CD62L⁺ T cells in TIL cells cultured after 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or 5 days after addition of OKT3 and IL-2. The results showed that the addition of feeder cells-cultured TIL after 12 hours or more after the addition of OKT3 and IL-2 had a higher proportion of memory T cells (Tcm, CD45RO ⁺CD62L⁺) than the simultaneous addition of feeder cells-cultured TIL.

FIG. 23 shows NK T cell fractions of TIL cells cultured with the addition of feeder cells after 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or 5 days of OKT3 and IL-2 addition. The results showed that the addition of feeder cells-cultured TIL after 12 hours or more after the addition of OKT3 and IL-2 had a higher proportion of NK T cells than the addition of feeder cells-cultured TIL at the same time.

FIG. 24 shows the proportion of CD4 ⁺CD25⁺Foxp3⁺ regulatory T cells (Treg) of TIL cells cultured after 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or 5 days of addition of OKT3 and IL-2. The results showed that the addition of feeder cells-cultured TIL after 12 hours or more after the addition of OKT3 and IL-2 had a smaller proportion of regulatory T cells than the simultaneous addition of feeder cells-cultured TIL.

EXAMPLE 6 detection of the killing Capacity of cultured TIL according to the application

For the second stage expanded TIL activation of 1.4 of example 1, the amount of cells expanded in the first stage was adjusted to a cell density of 5X 10 ⁵ to 2X 10 ⁶/mL, and a CD3 antibody, e.g., OKT3, was added at a concentration of about 30ng/mL to 1 mL/well in a 24-well suspension culture plate, and IL-2, e.g., 3000 or 6000IU/mL, was added at a concentration of about 1000 to 9000 IU/mL. After 12 hours to 14 days, e.g. 48 hours, following the addition of OKT3 and IL-2 as described above, feeder cells are added to the culture environment of tumor-infiltrating lymphocytes. Wherein TIL and feeder cells can be added in a ratio of 1:40 to 1:400, and all cells are collected after about 9-14 days of expansion culture in the second stage, and the cell killing ability of the TIL obtained by the culture is detected and counted.

Cell preparation

TIL obtained from each test group for detection and target cells (e.g., a375 melanoma cells and/or Hela cervical cancer cells) for co-culture were prepared.

Detection step

Tumor cells were labeled with CFSE (5 (6) -Carboxyfluorescein DIACETATE N-succinimidyl ester, sigma,21888-25 MG-F): tumor cells were washed with PBS and resuspended in 500 μl PBS; CFSE was added to 500 μl of PBS and mixed with 500 μl of tumor cell PBS resuspension to a final CFSE concentration of 0.5 μmol/L. After incubation at 37℃for 6 minutes, the cells were washed with medium containing 10% FBS, centrifuged at 600g for 5 minutes, and resuspended at a tumor Cell concentration of 1X 10 ⁶ cells/mL in X-vivo 15 medium or other commercially available T Cell medium, e.g., stem Cell, lonza, thermo, meter-Tine, etc. The TIL population of each test group was centrifuged at 600g for 5 minutes to re-suspend TIL cells at an effective target ratio (TIL cell to tumor cell ratio) of 3:1 (i.e., at a concentration of 3 x 10 ⁶ cells/mL). Tumor cells and TIL cells were added 100. Mu.L each in U-bottom 96 well plates (Corning), and three wells were placed in each group. A control group containing only tumor cells was also set. The well plate was centrifuged at 200g for 1 min and incubated at 37℃for 4 hours to overnight. Wherein, when TIL is co-cultured with tumor cells, a substance which activates TIL cells can be not added as an inactive group, or transACT (Miltenyi, a nanomatrix material containing CD3 antibody and CD28 antibody) can be added as an active group.

After completion of incubation, 600g was centrifuged for 3 minutes, the supernatant was discarded, 20. Mu.L of pancreatin was added to each well, and the cells were digested by incubation in an incubator at 37℃for 3 to 5 minutes, and after completion of the digestion, the digestion was stopped by adding 180. Mu.L of medium containing 10% FBS. Dapi (Biyun, C0060) was treated with 1:100 dilutions were then added to each well with 20 μl of diluted Dapi. And (5) performing stream-type on-machine detection.

Killing rate% = Dapi ⁺CFSE⁺ cells/total CFSE ⁺ x 100%, or killing rate may be expressed by Dapi ⁺ cells/total tumor cells.

FIG. 25 shows the results of the cell killing ability of TIL cells cultured with the addition of feeder cells 48 hours after the addition of OKT3 and IL-2. The results show that TIL cultured with feeder cells added 48 hours after OKT3 and IL-2 addition has significant tumor cell killing capacity, such as melanoma and/or cervical tumor.

Example 7

Safety and effectiveness of tumor infiltrating lymphocytes of the application

The immune system of the subject may be treated prior to administration of the TIL to the subject, e.g., cyclophosphamide and/or fludarabine may be administered to the subject from day 4 to day 2 prior to administration of the TIL obtained by the culture method to the subject. For example, cyclophosphamide is administered at a dose of about 300 to 500mg/m ²/day and fludarabine is administered at a dose of 20 to 30mg/m ²/day. For example, the TIL of the present application may be administered intravenously to the subject at one time with a cell number of 5 x10 ⁹ to 1 x10 ¹¹. 8 to 16 hours after administration of the TIL, the IL-2 (or variant thereof) may be administered to the subject for the first time at a dose of 200,000 to 600,000IU/kg/time, the IL-2 administration may be suspended once after the IL-2 administration, and the IL-2 may be administered to the subject every 12 hours depending on the tolerability of the subject. The IL-2 may be administered to the subject 10 times, and the number of IL-2 administrations may be reduced depending on the tolerance of the subject. For the treatment regimen of tumor-infiltrating lymphocytes (TILs) of the application, the efficacy and safety of tumor patients were assessed.

Criteria for inclusion

Exclusion criteria

Clinical assessment protocol:

clinical data results show that the efficacy of two cervical cancer patients is assessed as Partial Remission (PR).

For example, for one advanced (recurrent and metastatic) cervical cancer patient, 4 cycles of docetaxel/cisplatin have passed through radical resections, and participated in bispecific antibody clinical trials; its ECOG score criteria (an indicator of the assessment of health and tolerance to treatment) was 1 point.

For safety, the patient is treated by the treatment method of the present application, does not have a safety event associated with the treatment of the present application, and is recovered after treatment. For effectiveness, as shown in fig. 26A and 26B, the imaging results indicate that the treatment method of the present application clinically exhibits excellent therapeutic effects, and both lesions achieve Partial Remission (PR) conditions.

The foregoing detailed description is provided by way of explanation and example and is not intended to limit the scope of the appended claims. Numerous variations of the presently exemplified embodiments will be apparent to those of ordinary skill in the art and remain within the scope of the appended claims and equivalents thereof.

Claims

Use of tumor-infiltrating lymphocytes (TILs) for the preparation of a medicament for the prevention and/or treatment of tumors, the TILs being obtained by the following culture method: the TIL derived from the tumor tissue is subjected to at least one stage of in vitro expansion, wherein in a single in vitro expansion stage, the in vitro expanded and/or non-in vitro expanded TIL is co-cultured with feeder cells after a certain time of contact with a T cell activator and/or a T cell growth factor.
The use according to claim 1, the culture method comprising subjecting TIL derived from tumor tissue to at least two stages of in vitro expansion, and in a second stage of in vitro expansion, co-culturing the in vitro expanded TIL with feeder cells after a certain time of contact with T cell activator and/or T cell growth factor.
The use of any one of claims 1-2, wherein the TIL obtained by co-culturing the TIL with the feeder cells after a certain time of contact with the T cell activator and/or T cell growth factor in a single in vitro expansion stage exhibits improved TIL properties compared to contacting the TIL with the T cell activator and/or T cell growth factor in a single in vitro expansion stage while co-culturing the TIL with the feeder cells.
The use of claim 3, the improved TIL characteristics comprising one or more selected from the group consisting of: increased TIL cell number and expansion capacity, increased viable cell fraction, increased persistence capacity, improved T cell subpopulation fraction, increased cytokine secretion capacity, increased tumor cell killing capacity, and increased T cell receptor

(TCR) clone diversity.
The use of claim 4, wherein the improved T cell subpopulation ratio comprises one or more selected from the group consisting of: increased central memory T cell fraction, decreased regulatory T cell fraction, increased activated T cell fraction, increased tumor specific T cell fraction, and increased stem cell-like T cell fraction.
The use of any one of claims 1-5, further comprising reducing the number of lymphocytes in the subject prior to administering the TIL obtained by the culture method to the subject.
The use of any one of claims 1-6, further comprising administering cyclophosphamide and/or fludarabine to a subject prior to administering to the subject the TIL obtained by the culture method.
The use of any one of claims 1-7, further comprising administering cyclophosphamide and/or fludarabine to the subject on days 4 to 2 prior to administering the TIL obtained by the culture method to the subject.
The use of any one of claims 1-8, wherein cyclophosphamide is administered to the subject at a dose of about 300 to about 500mg/m ²/day.
The use of any one of claims 1-9, wherein cyclophosphamide is administered to the subject for 3 days.
The use of any one of claims 1-10, wherein fludarabine is administered to the subject at a dose of about 20 to about 30mg/m ²/day.
The use of any one of claims 1-11, wherein fludarabine is administered to the subject for 3 days.
The use of any one of claims 1-12, further comprising administering the TIL obtained by the culture method to a subject with a cell number of about 5 x 10 ⁹ to about 1 x 10 ¹¹.
The use of any one of claims 1-13, further comprising administering the TIL obtained by the culture method to a subject in a single intravenous infusion.
The use of any one of claims 1-14, further comprising maintaining the TIL proliferative capacity after administration of the TIL obtained by the culture method to a subject.
The use of any one of claims 1-15, further comprising administering interleukin-2 (IL-2) or a variant thereof to the subject after administering the TIL obtained by the culturing method to the subject.
The use of any one of claims 1-16, wherein IL-2 is administered to the subject at a dose of about 200,000 to about 600,000IU/kg/dose.
The use of any one of claims 1-17, further comprising administering IL-2 to the subject for the first time 8 to 16 hours after administering the TIL obtained by the culture method to the subject.
The use of any one of claims 1-18, wherein after a first administration of IL-2 to a subject, IL-2 is administered to the subject every 12 hours.
The use of any one of claims 1-19, wherein the IL-2 is administered a second time 24 hours after the first administration of IL-2 to the subject, depending on the tolerability of the subject.
The use of any one of claims 1-20, wherein IL-2 is administered to the subject 10 times or less.
The use according to any one of claims 1-21, the culture method comprising: the TIL derived from tumor tissue is subjected to a first stage in vitro amplification and a second stage in vitro amplification, and in the second stage in vitro amplification, the TIL is co-cultured with the feeder cells.
The use of claim 22, wherein the first stage in vitro amplification is performed for at least about 7 days.
The use of any one of claims 22-23, wherein the first stage in vitro amplification is performed for about 7 days to about 14 days.
The use of any one of claims 22-24, wherein the second stage in vitro amplification is performed for at least about 7 days.
The use of any one of claims 22-25, wherein the second stage in vitro amplification is performed for about 7 days to about 14 days.
The use of any one of claims 1-26, wherein the TIL is co-cultured with the feeder cells after at least about 2 hours of contact with a T cell activator and/or a T cell growth factor.
The use of any one of claims 1-27, wherein the TIL is co-cultured with the feeder cells after being contacted with the T cell activator and/or the T cell growth factor for about 6 hours to about 72 hours.
The use of any one of claims 1-28, wherein the TIL is co-cultured with the feeder cells after being contacted with the T cell activator and/or the T cell growth factor for about 12 hours to about 48 hours.
The use of any one of claims 1-29, wherein the TIL is co-cultured with the feeder cells after about 6 hours, about 12 hours, about 24 hours, about 48 hours, or about 72 hours of contact with the T cell activator and/or the T cell growth factor.
The use of any one of claims 1-30, wherein the feeder cells comprise antigen presenting cells.
The use of any one of claims 1-31, wherein the feeder cells comprise one or more selected from the group consisting of: peripheral mononuclear cells, dendritic cells and artificial antigen presenting cells.
The use of any one of claims 1-32, wherein the feeder cells are peripheral mononuclear cells.
The use of any one of claims 1-33, wherein the feeder cells are irradiated feeder cells.
The use of any one of claims 1-34, wherein co-culturing the TIL with the feeder cells comprises contacting a surface of the feeder cells with a surface of the TIL.
The use of any one of claims 1-35, wherein co-culturing the TIL with the feeder cells comprises adding the feeder cells to a cell culture medium of the TIL.
The use of any one of claims 1-36, wherein the feeder cells are added to the cell culture medium of the TIL in a ratio of the feeder cells to the TIL of about 40:1 to about 400:1.
The use of any one of claims 1-37, the culture method further comprising: passing TIL derived from tumor tissue through at least one stage of in vitro expansion, wherein in the at least one stage of in vitro expansion, the TIL is contacted with the T cell activator.
The use of claim 38, wherein the TIL is contacted with the T cell activator in a single stage of the in vitro expansion.
The use of any one of claims 1-39, subjecting the TIL derived from tumor tissue to a first stage in vitro amplification and a second stage in vitro amplification, and in the second stage in vitro amplification, contacting the TIL with the T cell activator.
The use of any one of claims 1-40, wherein the T cell activator comprises one or more selected from the group consisting of: cluster of differentiation 80 (CD 80), CD86, CD276, 4-1BB ligand (4-1 BBL), CD27, CD30, CD134, CD275, CD40, CD258, and functionally active fragments thereof.
The use of any one of claims 1-41, wherein the T cell activator comprises an agonist of one or more targets selected from the group consisting of: CD3, CD28, herpes Virus Entry Medium (HVEM), CD40L, OX, 40 and 4-1BB.
The use of any one of claims 1-42, wherein the T cell activator comprises a CD3 agonist and/or a CD28 agonist.
The use according to any one of claims 1-43, wherein the T cell activator comprises a CD3 agonist.
The use according to any one of claims 1 to 44, wherein the T cell activator comprises an anti-CD 3 antibody and/or antigen binding fragment thereof.
The use of any one of claims 1-45, wherein the T cell activator comprises a CD28 agonist.
The use of any one of claims 1-46, wherein the T cell activator comprises an anti-CD 28 antibody and/or antigen-binding fragment thereof, CD80 and/or functionally active fragment thereof, and/or CD86 and/or functionally active fragment thereof.
The use of any one of claims 1-47, the contacting a TIL with the T cell activator comprising one or more means selected from the group consisting of: (1) Adding the T cell activator to a cell culture medium of the TIL; (2) Adding an engineered cell expressing the T cell activator to a cell culture medium of the TIL; and (3) adding a solid phase medium comprising the T cell activator to the cell culture medium of the TIL.
The use of claim 48, wherein each of said T cell activators is independently present in said TIL in a cell culture medium at an initial concentration of at least about 30ng/mL.
The use of any one of claims 48-49, wherein the initial concentration of each of the T cell activators in the cell culture medium of the TIL is each independently from about 30ng/mL to about 300ng/mL.
The use of any one of claims 48-50, wherein the diameter of the solid phase medium is from about 500 nm to about 10 microns.
The use of any one of claims 48-51, wherein the diameter of the solid phase medium is from about 1 nm to about 500 nm.
The use according to any one of claims 51-52, wherein the diameter of the solid phase medium is measured by transmission electron microscopy.
The use according to any one of claims 48-53, wherein the solid medium comprises a polymer.
The use of any one of claims 48-54, each independently comprising an amount of at least about 25 μg per mg of each of the T cell activator contained in the solid phase medium.
The use of any one of claims 48-55, wherein the solid phase medium comprising the T cell activator is added to the cell culture medium of the TIL in a ratio of about 2:1 to about 1:2 of the solid phase medium to the TIL.
The use of any one of claims 48-56, wherein the solid phase medium comprising the T cell activator is added to the cell culture medium of the TIL in a ratio of the solid phase medium to the TIL of about 1:100 to about 1:2000.
The use of any one of claims 1-57, the culture method further comprising: passing TIL derived from tumor tissue through at least one stage of in vitro amplification, wherein in the at least one stage of in vitro amplification, the TIL is contacted with the T cell growth factor.
The use of claim 58, wherein said TIL is contacted with said T cell growth factor in a single stage of said in vitro expansion.
The use of any one of claims 58-59, wherein the TIL is contacted with the T cell activator and the T cell growth factor in the single stage of the in vitro expansion.
The use of any one of claims 1-60, subjecting the TIL derived from tumor tissue to a first stage in vitro amplification and a second stage in vitro amplification, and contacting the TIL with a T cell growth factor in the first stage in vitro amplification and second stage in vitro amplification.
The use of claim 61, wherein said TIL is contacted with said T cell activator and said T cell growth factor substantially simultaneously in said second stage of in vitro expansion.
The use of any one of claims 1-62, wherein the T cell growth factor is selected from one or more of the following group: IL-2, IL-7, IL-12, IL-15, IL-21, interferon gamma, and functionally active fragments thereof.
The use of any one of claims 1-63, wherein the T cell growth factor comprises IL-2 and/or a functionally active fragment thereof.
The use of any one of claims 1-64, wherein contacting the TIL with the T cell growth factor comprises adding the T cell growth factor to a cell culture medium of the TIL.
The use of any one of claims 1-65, each of the T cell growth factors independently having an initial concentration of at least about 300IU/mL in the cell culture medium of the TIL.
The use of any one of claims 1-66, wherein the TIL derived from tumor tissue is selected from the group consisting of: TIL from fragments of tumor tissue, TIL from fragments of lymphatic metastases, TIL from pleural effusion, TIL from peritoneal effusion, TIL from tumor resection, TIL from biopsy and TIL from resuscitation after cryopreservation.
The use of claim 67, wherein said fragments have a volume of about 1 cubic millimeter to about 27 cubic millimeters.
The use of any one of claims 1-68, wherein the tumor is a solid tumor.
The use of any one of claims 1-69, wherein the tumor is selected from one or more of the following: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer, and renal cancer.
Use of tumor-infiltrating lymphocytes (TILs) for the preparation of a medicament for the prevention and/or treatment of tumors, the TILs being obtained by the following culture method:

(A) Contacting a first population of TILs derived from tumor tissue and not expanded in vitro with T cell growth factors, wherein a second population of TILs is obtained via said step (a);

(B) Co-culturing the second population of TILs with feeder cells after a time of contact with a T cell activator and/or a T cell growth factor, wherein a third population of TILs is obtained via step (B).
Use of tumor-infiltrating lymphocytes (TILs) for the preparation of a medicament for the prevention and/or treatment of tumors, the TILs being obtained by the following culture method:

(A) Resuscitating and/or continuing to culture an in vitro population of TILs to obtain a second population of TILs, wherein the in vitro population of TILs comprises a population of TILs obtained by ex vivo expansion of a first population of TILs derived from tumor tissue and not expanded in vitro;

(B) Co-culturing the second population of TILs with feeder cells after a time of contact with a T cell activator and/or a T cell growth factor, wherein a third population of TILs is obtained via step (B).
The use of claim 72, wherein the in vitro population of TILs comprises a population of TILs obtained from the first population of TILs contacted with a T cell growth factor.
The use of any one of claims 72-73, the in vitro population of TILs comprising a population of TILs obtained from cryopreservation of the first population of TILs.
The use of any one of claims 71-74, wherein step (a) is performed for about 7 days to about 14 days.
The use of any one of claims 71-75, wherein step (B) is performed for about 7 days to about 14 days.
Use of tumor-infiltrating lymphocytes (TILs) for the preparation of a medicament for the prevention and/or treatment of tumors, the TILs being obtained by the following culture method:

(A) Contacting a first population of TILs derived from tumor tissue and not expanded in vitro with T cell growth factors, wherein a second population of TILs is obtained via said step (a);

(B) Contacting the second population of TILs with a T cell activator and/or a T cell growth factor, wherein a third population of TILs is obtained via step (B);

(C) Co-culturing the third population of TILs with feeder cells, wherein a fourth population of TILs is obtained via step (C).
Use of tumor-infiltrating lymphocytes (TILs) for the preparation of a medicament for the prevention and/or treatment of tumors, the TILs being obtained by the following culture method:

(A) Resuscitating and/or continuing to culture an in vitro population of TILs to obtain a second population of TILs, wherein the in vitro population of TILs comprises a population of TILs obtained by ex vivo expansion of a first population of TILs derived from tumor tissue and not expanded in vitro;

(B) Contacting the second population of TILs with a T cell activator and/or a T cell growth factor, wherein a third population of TILs is obtained via step (B);

(C) Co-culturing the third population of TILs with feeder cells, wherein a fourth population of TILs is obtained via step (C).
The use of claim 78, the in vitro population of TILs comprising a population of TILs obtained from the first population of TILs contacted with a T cell growth factor.
The use of any one of claims 78-79, the in vitro population of TILs comprising a population of TILs obtained from cryopreservation of the first population of TILs.
The use of any one of claims 77-80, wherein step (a) is performed for about 7 days to about 14 days.
The use of any one of claims 77-81, wherein step (B) is performed for about 0 to about 8 days.
The use of any one of claims 77-82, wherein step (C) is performed for about 5 days to about 14 days.
The use of any one of claims 71-83, wherein the TIL obtained by co-culturing the TIL with feeder cells after a time of contact with a T cell activator and/or a T cell growth factor in a single in vitro expansion stage exhibits improved properties of the TIL compared to contacting the TIL with a T cell activator and/or a T cell growth factor while co-culturing the TIL with feeder cells in a single in vitro expansion stage.
The use of claim 84, the improved TIL characteristics comprising one or more selected from the group consisting of: increased TIL cell number and expansion capacity, increased proportion of living cells, increased persistence capacity, improved proportion of T cell subsets, increased cytokine secretion capacity, increased tumor cell killing capacity, and increased T Cell Receptor (TCR) clonal diversity.
The use of claim 85, the improved T cell subpopulation ratio comprising one or more selected from the group consisting of: increased central memory T cell fraction, decreased regulatory T cell fraction, increased activated T cell fraction, increased tumor specific T cell fraction, and increased stem cell-like T cell fraction.
The use of any one of claims 71-86, further comprising reducing the number of lymphocytes in a subject prior to administering the TIL obtained by the culture method to the subject.
The use of any one of claims 71-87, further comprising administering cyclophosphamide and/or fludarabine to a subject prior to administering the TIL obtained by the culture method to the subject.
The use of any one of claims 71-88, further comprising administering cyclophosphamide and/or fludarabine to a subject on days 4-2 prior to administering the TIL obtained by the culture method to the subject.
The use of any one of claims 71-89, wherein cyclophosphamide is administered to a subject at a dose of about 300 to about 500mg/m ²/day.
The use of any one of claims 71-90, wherein cyclophosphamide is administered to a subject for 3 days.
The use of any one of claims 71-91, wherein fludarabine is administered to the subject at a dose of about 20 to about 30mg/m ²/day.
The use of any one of claims 71-92, wherein fludarabine is administered to the subject for 3 days.
The use of any one of claims 71-93, further comprising administering the TIL obtained by the culture method to a subject with a cell number of about 5 x 10 ⁹ to about 1 x 10 ¹¹.
The use of any one of claims 71-94, further comprising administering the TIL obtained by the culture method to a subject in a single intravenous infusion.
The use of any one of claims 71-95, further comprising maintaining the TIL obtained by the culture method in proliferative capacity after administration of the TIL to a subject.
The use of any one of claims 71-96, further comprising administering interleukin-2 (IL-2) or a variant thereof to the subject after administering the TIL obtained by the culture method to the subject.
The use of any one of claims 71-97, wherein IL-2 is administered to the subject at a dose of about 200,000 to about 600,000IU/kg/dose.
The use of any one of claims 71-98, further comprising administering IL-2 to a subject for the first time 8 to 16 hours after administration of TIL obtained by the culture method to the subject.
The use of any one of claims 71-99, wherein after the first administration of IL-2 to a subject, IL-2 is administered to the subject every 12 hours.
The use of any one of claims 71-100, wherein the IL-2 is administered a second time 24 hours after the first administration of IL-2 to the subject, depending on the tolerability of the subject.
The use of any one of claims 71-101, wherein IL-2 is administered to a subject 10 times or less.
The use of any one of claims 71-102, wherein the TIL is co-cultured with the feeder cells after at least about 2 hours of contact with a T cell activator and/or a T cell growth factor.
The use of any one of claims 71-103, wherein the TIL is co-cultured with the feeder cells after being contacted with the T cell activator and/or the T cell growth factor for about 6 hours to about 72 hours.
The use of any one of claims 71-104, wherein the TIL is co-cultured with the feeder cells after being contacted with the T cell activator and/or the T cell growth factor for about 12 hours to about 48 hours.
The use of any one of claims 71-105, wherein the TIL is co-cultured with the feeder cells after about 6 hours, about 12 hours, about 24 hours, about 48 hours, or about 72 hours of contact with the T cell activator and/or the T cell growth factor.
The use of any one of claims 71-106, wherein the feeder cells comprise antigen presenting cells.
The use of any one of claims 71-107, wherein the feeder cells comprise one or more selected from the group consisting of: peripheral mononuclear cells, dendritic cells and artificial antigen presenting cells.
The use of any one of claims 71-108, wherein the feeder cells are peripheral mononuclear cells.
The use of any one of claims 71-109, wherein the feeder cells are irradiated feeder cells.
The use of any one of claims 71-110, wherein co-culturing the TIL with the feeder cells comprises contacting a surface of the feeder cells with a surface of the TIL.
The use of any one of claims 71-111, wherein co-culturing the TIL with the feeder cells comprises adding the feeder cells to a cell culture medium of the TIL.
The use of any one of claims 71-112, wherein the feeder cells are added to the cell culture medium of the TIL in a ratio of the feeder cells to the TIL of about 40:1 to about 400:1.
The use of any one of claims 71-113, the T cell activator comprising one or more selected from the group consisting of: cluster of differentiation 80 (CD 80), CD86, CD276, 4-1BB ligand (4-1 BBL), CD27, CD30, CD134, CD275, CD40, CD258, and functionally active fragments thereof.
The use of any one of claims 71-114, wherein the T cell activator comprises an agonist of one or more targets selected from the group consisting of: CD3, CD28, herpes Virus Entry Medium (HVEM), CD40L, OX, 40 and 4-1BB.
The use of any one of claims 71-115, wherein the T cell activator comprises a CD3 agonist and/or a CD28 agonist.
The use of any one of claims 71-116, wherein the T cell activator comprises a CD3 agonist.
The use of any one of claims 71-117, wherein the T cell activator comprises an anti-CD 3 antibody and/or antigen-binding fragment thereof.
The use of any one of claims 71-118, wherein the T cell activator comprises a CD28 agonist.
The use of any one of claims 71-119, wherein the T cell activator comprises an anti-CD 28 antibody and/or antigen-binding fragment thereof, CD80 and/or functionally active fragment thereof, and/or CD86 and/or functionally active fragment thereof.
The use of any one of claims 71-120, the contacting a TIL with the T cell activator comprising one or more means selected from the group consisting of: (1) Adding the T cell activator to a cell culture medium of the TIL; (2) Adding an engineered cell expressing the T cell activator to a cell culture medium of the TIL; and (3) adding a solid phase medium comprising the T cell activator to the cell culture medium of the TIL.
The use of claim 121, wherein the initial concentration of each of the T cell activators in the cell culture medium of the TIL is, independently, at least about 30ng/mL.
The use of any one of claims 121-122, wherein the initial concentration of each of the T cell activators in the cell culture medium of the TIL is each independently from about 30ng/mL to about 300ng/mL.
The use of any one of claims 121-123, wherein the diameter of the solid phase medium is about 500 nm to about 10 microns.
The use of any one of claims 121-124, wherein the diameter of the solid phase medium is about 1 nm to about 500 nm.
The use of any one of claims 124-125, the diameter of the solid phase medium being measured by transmission electron microscopy.
The use of any one of claims 121-126, wherein the solid medium comprises a polymer.
The use of any one of claims 121-127, each independently comprising an amount of at least about 25 μg per mg of each of the T cell activator contained in the solid phase medium.
The use of any one of claims 121-128, wherein the solid phase medium comprising the T cell activator is added to the cell culture medium of the TIL in a ratio of about 2:1 to about 1:2 of the solid phase medium to the TIL.
The use of any one of claims 121-129, wherein the solid phase medium comprising the T cell activator is added to the cell culture medium of the TIL in a ratio of the solid phase medium to the TIL of about 1:100 to about 1:2000.
The use of any one of claims 71-130, wherein the TIL is contacted with the T cell activator and the T cell growth factor substantially simultaneously.
The use of any one of claims 71-131, wherein the T cell growth factor is selected from one or more of the group consisting of: IL-2, IL-7, IL-12, IL-15, IL-21, interferon gamma, and functionally active fragments thereof.
The use of any one of claims 71-132, wherein the T cell growth factor comprises IL-2 and/or a functionally active fragment thereof.
The use of any one of claims 71-133, wherein contacting the TIL with the T cell growth factor comprises adding the T cell growth factor to a cell culture medium of the TIL.
The use of any one of claims 71-134, wherein the initial concentration of each of the T cell growth factors in the cell culture medium of the TIL is each independently at least about 300IU/mL.
The use of any one of claims 71-135, wherein the TIL derived from tumor tissue is selected from the group consisting of: TIL from fragments of tumor tissue, TIL from fragments of lymphatic metastases, TIL from pleural effusion, TIL from peritoneal effusion, TIL from tumor resection, TIL from biopsy and TIL from resuscitation after cryopreservation.
The use of claim 136, wherein the fragments have a volume of about 1 cubic millimeter to about 27 cubic millimeters.
The use of any one of claims 71-137, wherein the tumor is a solid tumor.
The use of any one of claims 71-138, wherein the tumor is selected from one or more of the following group: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer, and renal cancer.
A pharmaceutical composition comprising the TIL obtained by the culture method according to any one of claims 1-139, and a substance that reduces the number of lymphocytes and/or a substance that maintains the proliferation capacity of the TIL.
The pharmaceutical composition of claim 140, wherein the lymphocyte depleting substance comprises cyclophosphamide and/or fludarabine.
The pharmaceutical composition of any one of claims 140-141, the substance that maintains the TIL in proliferative capacity comprising interleukin-2 (IL-2) or a variant thereof.
The pharmaceutical composition of any one of claims 140-142, comprising the cyclophosphamide at a dose of about 300 to about 500mg/m ²/day.
The pharmaceutical composition of any one of claims 140-143, comprising the fludarabine at a dose of about 20 to about 30mg/m ²/day.
The pharmaceutical composition of any one of claims 140-144, comprising the IL-2 at a dose of about 200,000 to about 600,000IU/kg/serving.
A kit comprising the pharmaceutical composition of any one of claims 140-145.